°Q½×°Ï>¤ß®®¥ÍÂå
Åý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O
·|­û:²q·Q 10136148 µoªí®É¶¡:2017/8/21 ¤U¤È 05:20:28
§N¼ö´`Àô , ¬O¥|©uªº¥²µM

º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM

¶}³o­Óª©¤D¦³·P©ó

Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×­z

Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O

¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P

©Ò¥H , ³o­Óª©

¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï

§Æ±æ¼ö¾x¬O­ì«h

¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý

¬ß±æ

¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú­Ìªº¦@¦Pµ§°O

¡yÅý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O

´Á«Ý±zªº°Ñ»P

ÁÂÁ¤j®a!

·|­û:YOYO10140343µoªí®É¶¡:2018/10/31 ¤W¤È 09:42:30²Ä1023½g¦^À³
¬Q¤é¶R¶W²Ä¤@¦W¬O¤¸¤jÂù©M,°·X¤j¤á¤w¦bÀqÀq¦Y³f,¤W¤@ªi¥L­Ì¦b70-80¦³½æ,³o¤@ªi¦^¸É¥L­Ì«ç»ò¶R³£Ä¹,¥[¤W©ú¦~²Ä¤@©u¶i¤J´Á¤¤¤ÀªR,±À´ú¦³¤£¿ùªº¦¨ªG,¦~©³ªÑªF·|À³¤£»Ý­n¤F,µ¥©ú¦~²Ä¤@©u´Á¤¤¤ÀªR¥X¨Ó,ªÑ»ù¤ÏÀ³«á¦A¨Ó°ê¤º¿ì²{¼W³£¨Óªº¤Î,³o®É­Ô¦A½æ¥X¨Óªº¤£´N¼ï¥J
·|­û:«Ó°¶10144972µoªí®É¶¡:2018/10/30 ¤W¤È 11:26:07²Ä1022½g¦^À³
¦nºG

¹j¾À¬P¬P¦b¦u30¡A§Ú­Ì¦b¦u50

³oªi¤U¶^·sÃĤS­«¦^¥h¦~­ìÂI¤F

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/10/26 ¤W¤È 10:21:15²Ä1021½g¦^À³
Biotech Investment Summit-¥Íª«¬ì§Þ§ë¸ê°ª®p·|-

¤é´Á¡G2018¦~10¤ë31¤é-11¤ë2¤é

¦aÂI¡GOne Farrer Hotel & Spa, Singapore

www.giievent.tw/ib652176/

Project Showcases: Beyond a Legacy of Academia

Emil Tsai, Chief Executive Officer, SyneuRx International (Taiwan) Corp

. Bridging the insurmountable gaps from academia to new drug development

. Establishing a scientific platform by confirmation of multiple converging new drug targets

. Incremental success can lead to paradigm shift in CNS drug discovery

·|­û:²q·Q10136148µoªí®É¶¡:2018/10/16 ¤U¤È 07:52:32²Ä1020½g¦^À³
ºë¯«ÃĪ«´âÓiଳQÀݥΧܧíÆ{§íÆ{¯g¤wµL·sÃÄ¥i¥Î¡H

¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-10-16

med.sina.com/article_detail_103_2_54169.html

¹L¥h´X¤Q¦~¡AÀHµÛ¤HÃþ¥Í¬¡¸`«µÅܤơA·s«¬ÃĪ«¬ãµo¡A§íÆ{¯g±wªÌ©M¨Ï¥Î§Ü§íÆ{ÃĪ«ªº¤H¼Æ¥¿¦b³v¦~¼W¥[¡C¾Ú¬ü°ê°ê®a½Ã¥Í²Î­p¤¤¤ß¡]NCHS¡^2017¦~µo¥¬ªº¤@¥÷³ø§iÅã¥Ü¡A¦b¬ü°ê12·³©Î¥H¤Wªº¤H¤¤ªñ13%ªA¥Î§Ü§íÆ{ÃÄ¡C±q1999¦~¨ì2014¦~¡A³o¤@¤ñ²v¼W¥[¤Fªñ65%¡CÄY­«ªº§íÆ{¯g¥¿¦b¼vÅT¥þ²yªñ3»õ¤H¡A¦P®É§íÆ{¯gÃĪ«ªº¥«³õ¹w­p¬ù¬°830»õ¬ü¤¸¡C

...

·|­û:²q·Q10136148µoªí®É¶¡:2018/10/10 ¤U¤È 03:15:18²Ä1019½g¦^À³
¹ï¤£°_! ¦A§ï¤@¤U»y·N¤£²Mªº¦a¤è

¤j®aÁÙ°O±o¶Ü?!

½²±Ð±Â°õ¦æÁ{§Éªº§@¬°

Considerations in Designing Phase 2/3 Registrational Trials for NaBen® as Adjunctive Therapy to Standard-Of-Care

Minimizing placebo responses

• Clinician training

 Understand placebo responses

 Do¡¦s and Don¡¦ts training to minimize physician cues that might induce placebo responses

 Script of honest answers to the assessment interview

Optimizing signal-to-noise in assessing patient responses

• Proprietary Quality Control algorithm to check quality and consistency in patient assessments

• Confirmation of the diagnosis and inclusion/exclusion criteria by central experts

• Standardize patient assessment processes

• Reminders to increase medication adherence and study follow-up

±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C

• Á{§ÉÂå®vªº°V½m

 ¤F¸Ñ¦w¼¢¾¯®ÄÀ³

 ¸Ó¬°©M¤£¸Ó¬°ªº°V½m , ¨ÓºÉ¶q´î¤ÖÂå®v´£¥Ü©Ò¥i¯à»¤¾Éªº¦w¼¢¾¯®ÄÀ³

 ¹w¥ýÀÀ¦n¸}¥»¨Ó¨ú±o­±½Í®É±wªÌ¯u¹êªº·P¨ü

¦bµû©w±wªÌ¤ÏÀ³ªº³Ì¨Î¤Æ°T¾¸¤ñ§@ªk

• Proprietary Quality Control ºâªk¡A¥Î©óÀˬd±wªÌµû¶qªº«~½è©M¤@­P©Ê

• ¤¤¤ßªº±M®a½T»{¶EÂ_©M¯Ç¤J / ±Æ°£¼Ð·Ç

• ¼Ð·Ç¤Æ±wªÌµû¦ôµ{§Ç

• ´£¿ô¥H¥[±jªAÃĨ̱q©Ê©M¬ã¨sÀH³X

Á{§É³]­p¥ÎSPCD

Á{§É°õ¦æ¥Î «e­z¹w«ØªºSOP

©Î³\¯à±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C , ¤£¦P¸ÕÅç¦aÂIªºµû¶q¨ú±o¤@­P¤Æ , ÁÙ¦³±wªÌªAÃĨ̱q©Ê

½²±Ð±Â°õ¦æÁ{§Éªº¿¦±K¶g¨ì©Ò²o¯A±M·~©M¸gÅç»P¥Î¤ß , ¹ê¥O§Ú­Ì·q¨Ø

¨ä¦¸ , §Ú­Ì¦A¨Ó±´°QSND-13 ¹LÃöªº¥i¯à©Ê ? ¤pªº±N¹Á¸Õ¤@­Ó«D±`²Ê²¤ªº¶q¤Æ¦ô­p

¥Ñ SND-13 ªº Primary Outcome Measures:

Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 8 weeks after randomized treatment ]

Mean change from baseline in PANSS total score

¤@­Ó«ü¼Ð

• Phase 2 trial for NaBen® (Lane et al; 2013) demonstrated a treatment effect size (ES) ~ 1.53

• Phase II/III registrational trial is designed to detect an ES >= 0.5 with 85% power

[ Cohen(1988)ªº«Øij¡A±N«¬¤@¿ù»~®e§Ô­È©w¬°5%¥B«¬¤G¿ù»~®e§Ô­È©w¬°20%¡A¤]´N¬O»¡¦pªG§Ú­Ì±o¨ìªº¼Ë¥»¸ê®Æ©Ò±À½×ªºp­È¤p©ó0.05¥Bpower°ª©ó80%®É¡A¨â­ÓÃþ«¬¿ù»~µo¥Í¾÷²v³£ÆZ§Cªº´N¥Nªí¤£ºÞ¥À¸sÅéµ²ªG¬°¦ó¡A§Ú­Ì±À½×ªºµ²ªG¥¦¥Ç¿ù¾÷²v³£¬O§Cªº¡A§Ú­Ì´N·|¹ï³o­Óµ²ªG«D±`ªº¦³«H¤ß¡I]

¦Ó®ÄªG¶q ES ¬O¬Æ»ò?

¡u¼Ë¥»¸ê®Æ©Ò±o¨ìªº®t²§¬O´X­Ó¼Ð·Ç®t¡v , ´«¥y¸Ü»¡ , ES = ¨â²Õ®t²§ / ¼Ð·Ç®t

¨â­ÓÃöÁ䪺¶q ¨â²Õ®t²§ ©M ¼Ð·Ç®t

²{¦b§Ú­Ì¬O­n®³ SND-13 ªº¤G´Á¨Ó±À¦ô¤T´Á¹LÃöªº¥i¯à©Ê , ©Ò¥H¥ý°²³]¨â­Ó´Á§Oªº¸ÕÅç²Õ©M¦w¼¢¾¯²Õ¦b6¶g®ÉªºÃĮĮt²§¤@¼Ë

¦ý¬O , ¤G¤T´Áªº¸ÕÅç®É¶¡¤£¤@¼Ë , ¤@­Ó6¶g , ¤@­Ó8¶g , ©Ò¥H¥Î¤G´ÁªºÃÄ®ÄÁͶչϦô­p , ¤T´Áªº®t²§¬ù¬°¤G´Áªº 1.2 ­¿

¨Æ¹ê¤W , §Ú­Ì«e¬q»¡ªº§@ªk­nºÉ¶q­°§C¦w¼¢¾¯®ÄÀ³ , ´N¬OÅý¨â²Õªº®t²§©Ô¤j¶ZÂ÷ , ¤£­nÅý¦w¼¢¾¯ªº®Ä¯q©¹¸ÕÅç²Õ¾aªñ , ÅýESÅܱo§ó¤j

¦Ó¼Ð·Ç®t©O ?

¼Ð·Ç®t©M¼Ë¥»¼Æ¦³Ãö

¼Ë¥»¼Æ¤G´Á¨ú27 , ¤T´Á©O ?

348*3/4 = 261 , °²³]¦³¤ÏÀ³ªÌ¦³3¦¨ , ¨º»ò°Ñ¥[Âùª¼¸ÕÅç«K¦³ 261*0.7 = 182 , ©Ò¥H¸ÕÅç²Õ©M¹ï·Ó²Õ¦U¦³91 ¤H

§Ú­Ì¥i¥Hºâ±o : ¤T´Á©M¤G´Áªº¼Ð·Ç®t , ¦³ ( 91/27)¶}®Ú¸¹ = 1.84 ­¿ªº®t­È , §Y¤T´Áªº¤À¥¬¦±½u·|¸û¤G´Áªº°~®k

¦]¦¹ , ²Ê²¤¦ô­p¤T´Á¤ñ¤§¤G´Áªº¦w¥þ«Y¼Æ = 1.2 *1.84*(1.53/0.5) = 6.7

°ª©Î§C ? ¦³½Ð¤j®a¦Û¦æµû§P

µM¤T´Á©M¤G´Á¦³«Ü¦h¥D«ÈÆ[Åܼƪº¤£¦P , ¦ô­p¼Æ­È¤Ó²ÊÁW½Ð¬Ý¬Ý´N¦n , ¤Á¤Å·í§ë¸ê¨Ì¾Ú

¶È¨Ñ°Ñ¦Ò

·q½Ð«ü¥¿¥´Áy

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/10/10 ¤U¤È 01:06:25²Ä1018½g¦^À³
§ó¥¿¤@­Ó¦r «e¤å[«o]¬°[¤Á]¤§»~

¤j®aÁÙ°O±o¶Ü?!

½²±Ð±Â°õ¦æÁ{§Éªº§@¬°

Considerations in Designing Phase 2/3 Registrational Trials for NaBen® as Adjunctive Therapy to Standard-Of-Care

Minimizing placebo responses

• Clinician training

 Understand placebo responses

 Do¡¦s and Don¡¦ts training to minimize physician cues that might induce placebo responses

 Script of honest answers to the assessment interview

Optimizing signal-to-noise in assessing patient responses

• Proprietary Quality Control algorithm to check quality and consistency in patient assessments

• Confirmation of the diagnosis and inclusion/exclusion criteria by central experts

• Standardize patient assessment processes

• Reminders to increase medication adherence and study follow-up

±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C

• Á{§ÉÂå®vªº°V½m

 ¤F¸Ñ¦w¼¢¾¯®ÄÀ³

 ¸Ó¬°©M¤£¸Ó¬°ªº°V½m , ¨ÓºÉ¶q´î¤ÖÂå®v´£¥Ü©Ò¥i¯à»¤¾Éªº¦w¼¢¾¯®ÄÀ³

 ¹w¥ýÀÀ¦n¸}¥»¨Ó¨ú±o­±½Í®É±wªÌ¯u¹êªº·P¨ü

¦bµû©w±wªÌ¤ÏÀ³ªº³Ì¨Î¤Æ°T¾¸¤ñ§@ªk

• Proprietary Quality Control ºâªk¡A¥Î©óÀˬd±wªÌµû¶qªº«~½è©M¤@­P©Ê

• ¤¤¤ßªº±M®a½T»{¶EÂ_©M¯Ç¤J / ±Æ°£¼Ð·Ç

• ¼Ð·Ç¤Æ±wªÌµû¦ôµ{§Ç

• ´£¿ô¥H¥[±jªAÃĨ̱q©Ê©M¬ã¨sÀH³X

Á{§É³]­p¥ÎSPCD

Á{§É°õ¦æ¥Î «e­z¹w«ØªºSOP

©Î³\¯à±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C , ¤£¦P¸ÕÅç¦aÂIªºµû¶q¨ú±o¤@­P¤Æ , ÁÙ¦³±wªÌªAÃĨ̱q©Ê

½²±Ð±Â°õ¦æÁ{§Éªº¿¦±K¶g¨ì©Ò²o¯A±M·~©M¸gÅç»P¥Î¤ß , ¹ê¥O§Ú­Ì·q¨Ø

¨ä¦¸ , §Ú­Ì¦A¨Ó±´°QSND-13 ¹LÃöªº¥i¯à©Ê ? ¤pªº±N¹Á¸Õ¤@­Ó«D±`²Ê²¤ªº¶q¤Æ¦ô­p

¥Ñ SND-13 ªº Primary Outcome Measures:

Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 8 weeks after randomized treatment ]

Mean change from baseline in PANSS total score

¤@­Ó«ü¼Ð

• Phase 2 trial for NaBen® (Lane et al; 2013) demonstrated a treatment effect size (ES) ~ 1.53

• Phase II/III registrational trial is designed to detect an ES >= 0.5 with 85% power

[ Cohen(1988)ªº«Øij¡A±N«¬¤@¿ù»~®e§Ô­È©w¬°5%¥B«¬¤G¿ù»~®e§Ô­È©w¬°20%¡A¤]´N¬O»¡¦pªG§Ú­Ì±o¨ìªº¼Ë¥»¸ê®Æ©Ò±À½×ªºp­È¤p©ó0.05¥Bpower°ª©ó80%®É¡A¨â­ÓÃþ«¬¿ù»~µo¥Í¾÷²v³£ÆZ§Cªº´N¥Nªí¤£ºÞ¥À¸sÅéµ²ªG¬°¦ó¡A§Ú­Ì±À½×ªºµ²ªG¥¦¥Ç¿ù¾÷²v³£¬O§Cªº¡A§Ú­Ì´N·|¹ï³o­Óµ²ªG«D±`ªº¦³«H¤ß¡I]

¦Ó®ÄªG¶q ES ¬O¬Æ»ò?

¡u¼Ë¥»¸ê®Æ©Ò±o¨ìªº®t²§¬O´X­Ó¼Ð·Ç®t¡v , ´«¥y¸Ü»¡ , ES = ¨â²Õ®t²§ / ¼Ð·Ç®t

¨â­ÓÃöÁ䪺¶q ¨â²Õ®t²§ ©M ¼Ð·Ç®t

²{¦b§Ú­Ì¬O­n®³ SND-13 ªº¤G´Á¨Ó±À¦ô¤T´Á¹LÃöªº¥i¯à©Ê , ©Ò¥H¥ý°²³]¸ÕÅç²Õ©M¦w¼¢¾¯²ÕªºÃĮĤ@¼Ë

¦ý¬O , ¤G¤T´Áªº¸ÕÅç®É¶¡¤£¤@¼Ë , ¤@­Ó6¶g , ¤@­Ó8¶g , ©Ò¥H¥Î¤G´ÁªºÃÄ®ÄÁͶչϦô­p , ¤T´Áªº®t²§¬ù¬°¤G´Áªº 1.2 ­¿

¨Æ¹ê¤W , §Ú­Ì«e¬q»¡ªº§@ªk­nºÉ¶q­°§C¦w¼¢¾¯®ÄÀ³ , ´N¬OÅý¨â²Õªº®t²§©Ô¤j¶ZÂ÷ , ¤£­nÅý¦w¼¢¾¯ªº®Ä¯q©¹¸ÕÅç²Õ¾aªñ

¦Ó¼Ð·Ç®t©O ?

¼Ð·Ç®t©M¼Ë¥»¼Æ¦³Ãö

¼Ë¥»¼Æ¤G´Á¨ú27 , ¤T´Á©O ?

348*3/4 = 261 , °²³]¦³¤ÏÀ³ªÌ¦³3¦¨ , ¨º»ò°Ñ¥[Âùª¼¸ÕÅç«K¦³ 261*0.7 = 182 , ©Ò¥H¸ÕÅç²Õ©M¹ï·Ó²Õ¦U¦³91 ¤H

§Ú­Ì¥i¥Hºâ±o : ¤T´Á©M¤G´Áªº¼Ð·Ç®t , ¦³ ( 91/27)¶}®Ú¸¹ = 1.84 ­¿ªº®t­È , §Y¤T´Áªº¤À¥¬¦±½u·|¸û¤G´Áªº°~®k

¦]¦¹ , ²Ê²¤¦ô­p¤T´Á¤ñ¤§¤G´Áªº¦w¥þ«Y¼Æ = 1.2 *1.84*(1.53/0.5) = 6.7

°ª©Î§C ? ¦³½Ð¤j®a¦Û¦æµû§P

µM¤T´Á©M¤G´Á¦³«Ü¦h¥D«ÈÆ[Åܼƪº¤£¦P , ¦ô­p¼Æ­È¤Ó²ÊÁW½Ð¬Ý¬Ý´N¦n , ¤Á¤Å·í§ë¸ê¨Ì¾Ú

¶È¨Ñ°Ñ¦Ò

·q½Ð«ü¥¿¥´Áy

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/10/10 ¤U¤È 12:59:59²Ä1017½g¦^À³
¤j®aÁÙ°O±o¶Ü?!

½²±Ð±Â°õ¦æÁ{§Éªº§@¬°

Considerations in Designing Phase 2/3 Registrational Trials for NaBen® as Adjunctive Therapy to Standard-Of-Care

Minimizing placebo responses

• Clinician training

 Understand placebo responses

 Do¡¦s and Don¡¦ts training to minimize physician cues that might induce placebo responses

 Script of honest answers to the assessment interview

Optimizing signal-to-noise in assessing patient responses

• Proprietary Quality Control algorithm to check quality and consistency in patient assessments

• Confirmation of the diagnosis and inclusion/exclusion criteria by central experts

• Standardize patient assessment processes

• Reminders to increase medication adherence and study follow-up

±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C

• Á{§ÉÂå®vªº°V½m

 ¤F¸Ñ¦w¼¢¾¯®ÄÀ³

 ¸Ó¬°©M¤£¸Ó¬°ªº°V½m , ¨ÓºÉ¶q´î¤ÖÂå®v´£¥Ü©Ò¥i¯à»¤¾Éªº¦w¼¢¾¯®ÄÀ³

 ¹w¥ýÀÀ¦n¸}¥»¨Ó¨ú±o­±½Í®É±wªÌ¯u¹êªº·P¨ü

¦bµû©w±wªÌ¤ÏÀ³ªº³Ì¨Î¤Æ°T¾¸¤ñ§@ªk

• Proprietary Quality Control ºâªk¡A¥Î©óÀˬd±wªÌµû¶qªº«~½è©M¤@­P©Ê

• ¤¤¤ßªº±M®a½T»{¶EÂ_©M¯Ç¤J / ±Æ°£¼Ð·Ç

• ¼Ð·Ç¤Æ±wªÌµû¦ôµ{§Ç

• ´£¿ô¥H¥[±jªAÃĨ̱q©Ê©M¬ã¨sÀH³X

Á{§É³]­p¥ÎSPCD

Á{§É°õ¦æ¥Î «e­z¹w«ØªºSOP

©Î³\¯à±N¦w¼¢¾¯®ÄÀ³´î¦Ü³Ì§C , ¤£¦P¸ÕÅç¦aÂIªºµû¶q¨ú±o¤@­P¤Æ , ÁÙ¦³±wªÌªAÃĨ̱q©Ê

½²±Ð±Â°õ¦æÁ{§Éªº¿¦±K¶g¨ì©Ò²o¯A±M·~©M¸gÅç»P¥Î¤ß , ¹ê¥O§Ú­Ì·q¨Ø

¨ä¦¸ , §Ú­Ì¦A¨Ó±´°QSND-13 ¹LÃöªº¥i¯à©Ê ? ¤pªº±N¹Á¸Õ¤@­Ó«D±`²Ê²¤ªº¶q¤Æ¦ô­p

¥Ñ SND-13 ªº Primary Outcome Measures:

Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 8 weeks after randomized treatment ]

Mean change from baseline in PANSS total score

¤@­Ó«ü¼Ð

• Phase 2 trial for NaBen® (Lane et al; 2013) demonstrated a treatment effect size (ES) ~ 1.53

• Phase II/III registrational trial is designed to detect an ES >= 0.5 with 85% power

[ Cohen(1988)ªº«Øij¡A±N«¬¤@¿ù»~®e§Ô­È©w¬°5%¥B«¬¤G¿ù»~®e§Ô­È©w¬°20%¡A¤]´N¬O»¡¦pªG§Ú­Ì±o¨ìªº¼Ë¥»¸ê®Æ©Ò±À½×ªºp­È¤p©ó0.05¥Bpower°ª©ó80%®É¡A¨â­ÓÃþ«¬¿ù»~µo¥Í¾÷²v³£ÆZ§Cªº´N¥Nªí¤£ºÞ¥À¸sÅéµ²ªG¬°¦ó¡A§Ú­Ì±À½×ªºµ²ªG¥¦¥Ç¿ù¾÷²v³£¬O§Cªº¡A§Ú­Ì´N·|¹ï³o­Óµ²ªG«D±`ªº¦³«H¤ß¡I]

¦Ó®ÄªG¶q ES ¬O¬Æ»ò?

¡u¼Ë¥»¸ê®Æ©Ò±o¨ìªº®t²§¬O´X­Ó¼Ð·Ç®t¡v , ´«¥y¸Ü»¡ , ES = ¨â²Õ®t²§ / ¼Ð·Ç®t

¨â­ÓÃöÁ䪺¶q ¨â²Õ®t²§ ©M ¼Ð·Ç®t

²{¦b§Ú­Ì¬O­n®³ SND-13 ªº¤G´Á¨Ó±À¦ô¤T´Á¹LÃöªº¥i¯à©Ê , ©Ò¥H¥ý°²³]¸ÕÅç²Õ©M¦w¼¢¾¯²ÕªºÃĮĤ@¼Ë

¦ý¬O , ¤G¤T´Áªº¸ÕÅç®É¶¡¤£¤@¼Ë , ¤@­Ó6¶g , ¤@­Ó8¶g , ©Ò¥H¥Î¤G´ÁªºÃÄ®ÄÁͶչϦô­p , ¤T´Áªº®t²§¬ù¬°¤G´Áªº 1.2 ­¿

¨Æ¹ê¤W , §Ú­Ì«e¬q»¡ªº§@ªk­nºÉ¶q­°§C¦w¼¢¾¯®ÄÀ³ , ´N¬OÅý¨â²Õªº®t²§©Ô¤j¶ZÂ÷ , ¤£­nÅý¦w¼¢¾¯ªº®Ä¯q©¹¸ÕÅç²Õ¾aªñ

¦Ó¼Ð·Ç®t©O ?

¼Ð·Ç®t©M¼Ë¥»¼Æ¦³Ãö

¼Ë¥»¼Æ¤G´Á¨ú27 , ¤T´Á©O ?

348*3/4 = 261 , °²³]¦³¤ÏÀ³ªÌ¦³3¦¨ , ¨º»ò°Ñ¥[Âùª¼¸ÕÅç«K¦³ 261*0.7 = 182 , ©Ò¥H¸ÕÅç²Õ©M¹ï·Ó²Õ¦U¦³91 ¤H

§Ú­Ì¥i¥Hºâ±o : ¤T´Á©M¤G´Áªº¼Ð·Ç®t , ¦³ ( 91/27)¶}®Ú¸¹ = 1.84 ­¿ªº®t­È , §Y¤T´Áªº¤À¥¬¦±½u·|¸û¤G´Áªº°~®k

¦]¦¹ , ²Ê²¤¦ô­p¤T´Á¤ñ¤§¤G´Áªº¦w¥þ«Y¼Æ = 1.2 *1.84*(1.53/0.5) = 6.7

°ª©Î§C ? ¦³½Ð¤j®a¦Û¦æµû§P

µM¤T´Á©M¤G´Á¦³«Ü¦h¥D«ÈÆ[Åܼƪº¤£¦P , ¦ô­p¼Æ­È¤Ó²ÊÁW½Ð¬Ý¬Ý´N¦n , «o¤Å·í§ë¸ê¨Ì¾Ú

¶È¨Ñ°Ñ¦Ò

·q½Ð«ü¥¿¥´Áy

ÁÂÁ¤j®a!

·|­û:YOYO10140343µoªí®É¶¡:2018/10/2 ¤W¤È 11:16:43²Ä1016½g¦^À³
§U¤ß®®¦b°ê¤º¤W¥«°Ê°_¨Ó,¤]¶V¨Ó¶Vªñ¤F,³{§C¶R½L«ùÄò¦Y³f

¡mÃÒ¥æ©Ò¡n±À°Ê¤W¥«¡AÃÒ¥æ©Ò¦hºÞ»ô¤U ®É³ø¸ê°T 2018¦~10¤ë2¤é ¤W¤È7:56

¡i®É³ø-¥x¥_¹q¡j¬°§l¤Þ°ê¤º¥~¥ø·~¦bÃÒ¥æ©Ò¤W¥«¡A¥DºÞ¾÷Ãö»PÃÒ¥æ©Òªñ¨ÓºA«×¿n·¥¶}©ñ¡A±Ä¦hºÞ»ô¤U±À°Ê°ê¤º¥~¥ø·~¨Ó¥x¤W¥«¡A¥]¬A±À°Ê¦h¤¸¤W¥«¤è®×¡B¤W¥«¼f¬d´Á¶¡¥Ñ8©PÁYµu¬°6©P¡B±À°Ê¤W¥«¤½¥q®ü¥~Âà§ë¸ê¤½¥q¦^¥x¤W¥«¡B©ñ¼e¬ì§Þ¨Æ·~¶°«O³W©wµ¥4¤j±¹¬I¡C¡@¦b¥DºÞ¾÷Ãö¤ÎÃÒ¥æ©Ò¤µ¦~¥H¨Ó§V¤O±À°Ê¥H¤U4¤j§ï­²¡A´Á¥´¯}¥H©¹Â¦³Ã¿ÆX¡A¥H¶}©ñªº«ººA¾Ö©ê·s¸gÀÙ¡A§l¤Þ°ê¤º¥~¥ø·~¨Ó¤W¥«¡C

¡@¤@¡B±À°Ê¦h¤¸¤W¥«¤è®×¡G

¡@ÃÒ¥æ©Ò©ó¤µ¦~±À°Ê¦h¤¸¤W¥«¤è®×¡A¶}©ñ¤j«¬·s³Ð¥ø·~±o§K°£Àò§Q¯à¤O±ø¥ó¥Ó½Ð¤W¥«¡C¸Ó¤è®×¤§¹ê¬I±N¹ï§Ú°ê°ª¥«­Èªº¿W¨¤Ã~¥ø·~¡A²£¥Í§ó°ª§l¤Þ¤O¡A¥¼¨ÓÃÒ¥æ©Ò°t¦X¬F©²¡u5+2¬Fµ¦¡v¡A±N«ùÄò¨ó§U¿W¨¤Ã~¥ø·~³W¹º¤W¥«¡C

¡@¤G¡B¤W¥«¼f¬d´Á¶¡¥Ñ8©PÁYµu¬°6©P¡G

¡@ÃÒ¥æ©Ò¾ã¦X­ì¦³¸g²z³¡ªù¼fij¤Î¤º³¡¼f¬d·|ij¡AÁYµuªÑ²¼¥Ó½Ð¤W¥«¼f¬d´Á­­¡A¤é«áªÑ²¼¥Ó½Ð¤W¥«®×¦Û°e¥ó¥Ó½Ð¤é°_ºâ¡A­ì«h©ó6©P¤º´£³ø¤W¥«¼fij©e­û·|¼fij¡A¥H´£¤É¤W¥«¼f¬d®Ä²v¡C

¡@¤T¡B±À°Ê¤W¥«¤½¥q®ü¥~Âà§ë¸ê¤½¥q¦^¥x¤W¥«¡G

¡@§Ú°ê¤W¥«¤½¥q­u®ü¥~§ë¸êªÌ²³¦h¡A¥Ø«eÃÒ¥æ©Ò¤wªì¨B¿z¿ï²Å¦X¦^¥x¤W¥«¸ê®æªº®ü¥~¤l¤½¥q¡A¨Ã³W¹º¬ÛÃö±À°Ê¦æµ{¡A­Y¥ø·~¦³·NÄ@¡A¥B¤l¤½¥qªº°]°È¤Î·~°È²Å¦X¿W¥ß©Ê¸ê®æ±ø¥ó¡AÃÒ¥æ©Ò±N¿n·¥»²¾É¡A¨ó§U¨ä¤l¤½¥q¦^¥x¤W¥«¡C

¡@¥|¡B©ñ¼e¬ì§Þ¨Æ·~¶°«O³W©w¡G

¡@¬°§l¤Þ¥~°ê¤j«¬¬ì§Þ¨Æ·~¨Ó¥x¥Ó½Ð¤W¥«¡AÃÒ¥æ©Ò¾A«×©ñ¼e¬ì§Þ¨Æ·~¶°«O­­¨î¡A¥¼¨Ó¬ì§Þ¤½¥q¤W¥««á6­Ó¤ë§Y¥i»â¦^¶°«OªÑ²¼1/4¡A¤§«á¨C©¡º¡6­Ó¤ë¦A»â1/4¡A¨Ã©óº¡2¦~«á¥þ¼Æ»â¦^¡C¸û¥Ø«eº¡1¦~»â¦^1/2¡B2¦~¥þ¼Æ»â¦^¡A§ó¨ã¼u©Ê¡C¡]·s»D¨Ó·½¡G¤u°Ó®É³ø¢w§f²Q¬ü¡þ¥x¥_³ø¾É¡^

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/27 ¤W¤È 06:20:07²Ä1015½g¦^À³
¼Æ¦ì®ü¬¥¦]¨Óŧ¡I§Aªº«Ä¤l¬V¤W¡u¼Æ¦ì®ü¬¥¦]¡v¤F¶Ü¡H

www.chinatimes.com/realtimenews/20180927000004-260410

¤µ¦~6¤ë¡A¥@¬É½Ã¥Í²Õ´¦b²Ä11ª©ªº¡m°ê»Ú¯e¯f¤ÀÃþ¡n¡]ICD-11¡^¥¿¦¡±N¡uºô¸ô¹CÀ¸¦¨Å}¡v¡]Internet Gaming Disorder¡^µø¬°¤@ºØ¡u¯f¡v¡A»P°sºë¡BµÒ¯ó¡B©@°Ø¦]¡B¬r«~©MÃĪ«ÀݥΨæC¡A³£¬O¤WÅ}ªººë¯«¯e¯f¡C¡]¤µ©P¥Z´£¨Ñ¡^

¡u¤WÅ}¡v¡A·|µo¥Í­þ¨Ç¤£¨}«áªG¡H°£¤F¼vÅTµø¤O¤£¨Îµ¥°ÝÃD¥~¡A°ª¶¯Âå¾Ç¤j¾Çªþ³]Âå°|ºë¯«¬ì¥D¥ôº[°Æ±Ð±Â¬_§ÓÂEªº¬ã¨s¤¤µo²{¡G¡uºô¸ô¦¨Å}ªÌ¦b¥\¯à©ÊºÏ¾_³y¼v¡]fMRI¡^¤Wªº¤j¸£¬¡¤Æ¤ÏÀ³Åã¥Ü¡A¦¨Å}ªÌ¦³©ö©ó´÷¨D³ê°_¥H¤Î½Ä°Ê±±¨î¤£¨}ªº°ÝÃD¡C¡v

¦ñÀHµÛºô¸ô¹CÀ¸¦¨Å}¦Ó¨Óªº¡AÁÙ¦³«Ä¤lªº±Mª`¤O¤£¶°¤¤¡B±¡ºü°ÝÃD¡BµJ¼{©M¹L°Êµ¥¡A§ó´c¤Æ¤F¦¨Å}ªºÄY­«©Ê¡C¡uÁ{§É¤Wµo²{¡A¡]ºô¸ô¦¨Å}¡^10¦~«e¬ù¥e´NÂåªÌªº6¤À¤§1¡A¦Ó¤µ¬O¤@¥b¥ª¥k¡A¾ã¾ã´£¤É¬ù2­¿¡v»N¦¼ªâ¤ÀªR¡A¡u¦P®É¬ù¦³3¤À¤§1ªÌ¡A±a¦³µJ¼{©Î¹L°Êµ¥±¡§Î¡C¡v

,,,

¡u°e¥L¶i¥h¯f©Ð®É¡A­n¥ý¸g¹L¨â¹Dªù¡A±N©Ò¦³¼Æ¦ì²£«~¦¬°_¨Ó¡A¥u³Ñ´«¬~¦çª«©M®ÑÄy¡C«e«á¦í¤F10¤Ñ¡Aª¨ª¨³­¦í3¤Ñ¡AªvÀø¹Lµ{¤¤¡A¦³ªA¥Îª`·N¤O¤£¶°¤¤ªºÃĪ«¡A¨C¤Ñ¤ß²z»²¾É¥~ÁÙ°µÅé¾Þ¡C¡v

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/26 ¤U¤È 12:49:08²Ä1014½g¦^À³
¤j³ÂªÑ¼ö¼é¦A°_¡ICanopy¯}ªÅ«e°ª¡BTilray³s¤T¶^¤î¨B

2018/09/26 12:14 Moneydj²z°]ºô

MoneyDJ·s»D 2018-09-26 12:14:25 °OªÌ ³¯­d ³ø¾É

tw.stock.yahoo.com/news/%E5%A4%A7%E9%BA%BB%E8%82%A1%E7%86%B1%E6%BD%AE%E5%86%8D%E8%B5%B7-canopy%E7%A0%B4%E7%A9%BA%E5%89%8D%E9%AB%98-tilray%E9%80%A3%E4%B8%89%E8%B7%8C%E6%AD%A2%E6%AD%A5-041425167.html

¥[®³¤j¤j³Â§Y±N¦Xªk¤Æ¡A¼ö¿ú´é¤J¨gª£¤j³ÂªÑ¡A¬ÛÃö·~ªÌ¥X²{Ãz¬µ©Êº¦´T¡C¶g¤G¥[®³¤j¤j³Â°Ó°]³ø¶Ç¨Î­µ¡B¤S¦³¤ÀªR®v¬Ý¦n¤j³Â°Ó¡A¿EÀy¤j³Â·~ªÌªÑ»ù¼u°ª¡C

IBD¡BMarketWatch³ø¾ÉºÙ¡A¥[®³¤jÃĥΤj³Â¼tAurora Cannabis¤½¥¬¤W©u°]³ø¡AÀ禬¦¨ªø¤T­¿¦Ü1,910¸U¥[¹ô¡FÀò§Q¬°7,990¸U¥[¹ô¡A°ª©ó¥h¦~¦P´ÁªºÁ«·l590¸U¥[¹ô¡C

¸Ó¤½¥qªí¥Ü¡A10¤ë17¤é°_¥[®³¤j®T¼Ö¥Î¤j³Â¦Xªk¤Æ¡A¦ô­p»Ý¨D±N¤j¼W¡A¤w¸g¼W¥[®w¦s¡A¨Ã¦b¥[®³¤j¦U¬Ù¦w±Æ¨Ñ³f³q¸ô¡C

Aurora CannabisÀò§Q©_°ª¡A¥D­n¬O¤jÁ|§ë¸ê¨ä¥L¦P·~¡A¥¬§½¾ãÅé¤j³Â·~ªº»ù­ÈÃì¡C¸Ó¤½¥q¦]¦¹³QÅA¬°¡u¤j³Â¬Éªºªi§J®L®ü·æ«Â¡v(Berkshire Hathaway of pot)¡Cªi§J®L®ü·æ«Â¬OªÑ¯«¤Úµá¯S°õ´xªº¥ø·~¡A¥H¾Õ©ó§ë¸êÀò§Q»D¦W¡CAurora¤w¦b¥[°ê±¾µP¡A¥¼¨Ó·Ç³Æ­u¬ü¤W¥«¡C

»P¦¹¦P®É¡A¥t¤@®a¥[°ê¤j³Â°ÓCanopy GrowthÀò±oBenchmark¤ÀªR®vMike Hickey«C·ý¡A¥Ø¼Ð»ù100¥[¹ô¡A¤j¬ù¤ñCanopy Growth·í«e»ù¦ì°ª¥X44%¤§¦h¡C¹L¥h¤T­Ó¤ë¨Ó¡ACanopy GrowthªÑ»ù¤jº¦71%¡B¹L¥h¤@¦~¨Ó§ó¦¨ªø¤»­¿¥H¤W(523%)¡C

¥t¥~¡A¤j³Â°ÓTilrayªí¥Ü¡A±N°t°e¤fªA¤j³ÂÃĪ«CBD 100¦Ü¤T®aÂå°|¡AªvÀø¨àµ£Åöíw¡C®ø®§ÅýTilrayªÑ»ù¤î¶^¦^¤É¡C

MoneyDJ iQuote³ø»ùÅã¥Ü¡ATilray¶g¤G(25¤é)¤Wº¦8.42%¦¬¦b107.88¬ü¤¸¡A²×¤î³s¤T¶^¡C¹L¥h¤T­Ó¥æ©ö¤é¨Ó¡ATilrayªÑ»ù¼É¶^54%¡C¥¼©Ô¦^¤§«e¡A¸Ó¤½¥q¥»¤ëº¦´T°ª¹F228%¡C

Canopy Growthº¦0.46%¦¬¦b52.74¬ü¤¸¡A¥´¯}¾ú¥v¦¬½L·s°ª¡C¤µ¦~¦Ü¤µ¤jº¦122.94%¡C

IBD¡BBarron`s¡BCNBC¥ý«e³ø¾É¡A¤K¤ë¥÷ºX¤U¾Ö¦³Corona°à°sªº°s°ÓConstellation Brands¡A¹ï¥[®³¤j¤j³Â°ÓCanopy Growth§ë¸ê4»õ¬ü¤¸¡C17¤é¥i¤f¥i¼ÖÃÒ¹ê¡A¦Ò¼{¦b¹B°Ê¶¼®Æ¤¤¥[¤J¤j³Â¤G×ô(Cannabidiol¡ACBD)¡A¤j³Â¤G×ô¬O¤j³Âªº«Dºë¯«¬¡©Ê¦¨¤À¡A¤£·|Åý¤H¿³¾Ä¡A¨Ã¦³§Üµoª¢¡B´î½w¯kµhªº¥\®Ä¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/26 ¤W¤È 07:33:04²Ä1013½g¦^À³
¦pªG¤j®a³£ªA¥ÎÁo©úÃÄ¡A·|«ç»ò¼Ë

Zaria Gorvett (¤ãùبȡP°ª«Â¯S )

2018¦~ 9¤ë 25¤é

www.bbc.com/ukchina/trad/vert-cap-45640376

¡mNature¡nµJÂI ªA¥ÎÁo©úÃĪº¤H¤f¥¿©úÅã¤W¤É

2018/7/10 ¾ã²z/½s¿è³¡

www.gbimonthly.com/2018/07/28200/

·|­û:YOYO10140343µoªí®É¶¡:2018/9/20 ¤W¤È 10:10:20²Ä1012½g¦^À³
ªÑ²¼¬O¤@­Ó¹s©Mªº¹CÀ¸,¦³¤H½ß¿ú§C»ù½æ¥X,¤~¦³¤H·|ÁÈ¿ú,³Ìªñ½æ¥Xªº¤H,¤£¤Ö¬O°ªÂI¶Rªº,¥i±¤±þ¦b¦¹ªi¬q§CÂI,·í§Ú­Ì¦³¾÷·|³{§C¶R¶i,·íµM­n§â´¤.¦~©³¦³²{¼W,§Q¦h¤£·|¯Ê®u.
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/19 ¤W¤È 11:55:21²Ä1011½g¦^À³
ª©¤Wªº¤j¤j­Ì...

Ãö©óIPOªº³¡¤À...¤½¥q°ª¼h¦ÛµM·|¼f·Vµû¦ô...¤£»Ý¦A¹L¦h´¢´ú»P°Q½×...

³Ì¥D­n¬ÝªºÁÙ¬O·sÃĶi«×...¥u­n·sÃĶi«×¶V¨Ó¶V¦n©¹ÃÄÃÒÁÚ¶i...

±Mª`°ò¥»­±ªº±M·~§ë¸êªÌ¤Î»{¦P¤½¥qªº¤jªÑªF¦ÛµM·|¥H¦æ°Ê¤ä«ù¤½¥q...

¤@¦p¤W­Ó¤ë..¸³¨ÆªøÃö«Y¤H¥H¦æ°Ê¤O®¼¤½¥q...¥H73.6¤¸¥ª¥kªº§¡»ù..¼W¥[¤F310±i«ùªÑ..

¤jªÑªF­Ó¤H®³¿ú¥X¨Ó¤O®¼¤½¥q..¼W¥[«ùªÑ...§Ú­Ìªø´Á§ë¸êªº¾Ô¤Í­Ì¦ÛµM¹ï¤½¥q¦³«H¤ß...

¥H¤W~~

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/19 ¤W¤È 11:33:02²Ä1010½g¦^À³
YOYO¤j...

Ãö©óIPOªº³¡¤À...¬Û«H¤½¥q°ª¼h·|¸g¹L¼f·Vªºµû¦ô...

¥H­Ó¤Hªº¬Ýªk...¦b¥xÆWIPOªº¸Ü...¥H¥Ø«e·sÃĶi«×...IPO·|«Ü¶¶§Q...

¤jªÑªF¦b­Ó¤Hªº§ë¸ê³¡¤À...«ùÄò¼W¥[«ùªÑ...¬Û«H¬O«Ü¦³«H¤ß...

ª©¤Wªø´Á§ë¸êªº¾Ô¤Í­Ì...¦³¨Ç¤w«ù¦³2¦~¦h...¦³¨Ç¤µ¦~­è¥[¤J...

­@¤ßµ¥«Ý...¸êª÷¥R¸ÎªÌ...¥i°u¶q¸òµÛ¤jªÑªF¥[½X...

¥H¤W~~

·|­û:ªY½à¼Æ¦r¬ü10147157µoªí®É¶¡:2018/9/19 ¤W¤È 11:30:58²Ä1009½g¦^À³
¤£·Q¬Ý¨ìªÑ²¼¤U¶^´N ¤£­n ¤T¤£¤­®É´N·t¥ÜªÑªFÁ{®É·|¥i¯à§ë²¼­nºMÂd®ü¥~IPO

¥xªÑ´XÀɪѲ¼ºMÂd®ø®§¥X¨Ó«á¤£³£¬O¶^¨ì¤£¦æ

¹ï®ü¥~ªÑ²¼¶R½æµ{§Ç¤£À´©M©È³Â·Ðªº¤H·íµM´N·|¥ý·Q½æªÑ²¼¤F

°·¥Ã©M¥Íª«¬Û¦üÃĪº³ß±dÃÄÃÒ³£«Üí

©Ò¥H¸òµÛ®ü¥~IPO¤]¤£©È

Áp¥ÍÃÄÁÙ¨S¸Ñª¼¦ý¤½¥q¦³¦bºMÂd¤§«e¶R¦^2¤d±i¦Û®aªÑ²¼

¤ß®®ÁÙ¨S¸Ñª¼

®ü¥~IPO«á¦UºØ¤½¥q°T®§«ç»ò¨Ó?

¤H®a°·¥Ã¬O¸Ñª¼«á¤U¿³Âd¡B®ü¥~IPO

¤ß®®ÁÙ¨S¸Ñª¼ ¤ß®®ÁÙ¨S¸Ñª¼ ¤ß®®ÁÙ¨S¸Ñª¼

¤ß®®¬O¥´ºâ­n¦b¸Ñª¼¤§«eºMÂd®ü¥~IPO¶Ü?

¦³¦h¤Ö§ë¸ê¤H­^¤å¦nªº¥i¥H¦Û¤v§ä¸Ñª¼Á{§É°T®§?

¤ÀªR­^¤å¨Ó·½®ø®§Á{§É¼Æ¾Ú¬O¦h¦nÁÙ¬O¦hÃa¡AµM«á§PÂ_ªÑ²¼¶R½æ

¦Ó¥BÁÙ¬O·sÃijoºØ±M·~¥Î»y«Ü¦hªº­^¤å®ø®§?

·|­û:YOYO10140343µoªí®É¶¡:2018/9/19 ¤W¤È 11:17:04²Ä1008½g¦^À³
¤½¥q¶Ò¸ê¬O½T©w,¦ý¬O¬O§_­n¥h°ê¥~IPO¡AÀ³¸ÓÁÙ¦bÆ[±æ,¦~©³ªÑªF·|¥D­n¬O¶Ò¸ê, ¥D­n¦]¯À¬O¦b°ê¥~ªºIPO¦¨¥»°ª,¨Ò¦p¬ü°ê­n¥x¹ô1»õ¥H¤W,­»´ä­n¥x¹ô3000¸U¥H¤W,¥xÆW¬Û¹ï«K©y¬ù1200¸U¡A¥[¤W°ê¥~ªºÃÒ¨éºÊ²zÄY®æ,¤½¥qªººÞ²z°ª¼h¦pªG­n¼ô±x°ê¥~±¾µPªºªk¥O,¥u¯àªá¤j¿ú½Ð«ß®v¤Î·í¦a©Ó¾P°Ó¡A¦ý±¾µP¤]¦³¥i¯à±¾¤£¤W¥h,±¾¤W¥h¤F¤£¨£±o¯à¤Þ¸ê¶i¨Ó,¨Ò¦p¶À¥ß¦¨M17´N¬O³Ì¦nªº¨Ò¤l,IPO¶O¥Î1»õªá¤U¥h¤F,ÁÙ¬O¤U¥«¡C¦Ü©ó¦b­»´ä±¾µP,¦pªG¸ò¤¤°ê¤j³°¨S¦³³sµ²,À³¸Ó¤]¬O§xÃø­«­«,¦b¥xÆW±¾µPµL½×IPO¸òSPO¤ñ¬ü°ê­»´ä¨Óªº®e©ö,IPO«á,¦b°ê¥~¥ÎADR©ÎGDRÄw¸ê¤]¬O¥i¥H. ³Ìªñ¥Í§Þ¤½¥qµû¦ô¦b°ê¥~±¾µPªºÁn­µ¤Ö¤F,¥D¦]¬O®Ä¯q¤£¨Î,¦Ó¦b­»´äIPO­n¸ò¤j³°³sµ²,¦ý¦b¬r¬Ì­]¨Æ¥ó¥[¤W¤¤¬ü¶T©ö°ÝÃDµ¥ºØºØ±¡ªp,«Ü¦h³£¥´°h°ó¹ª¤F.½Ð°Ñ¦Ò¥H¤U¤å³¹:

www.genetinfo.com/investment/featured/item/18230.html?limitstart=0

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/19 ¤W¤È 10:46:53²Ä1007½g¦^À³
°ò¥»­±...

¤µ¦~·sÃĤj¶i«×..¼~Æ{¯g¸g¬ü°êFDA®Ö­ã¶i¤J¤T´Á..

¼~Æ{¯g¤@¦~116»õ¬ü¤¸¥H¤Wªº¥«³õ~~·Q¦X§@ªº°ê»Ú¤j¼t¦ÛµM«Ü¦h...

Äw½X­±...

¤d±i«ùªÑ¦bW25©P¦¬½L§¡»ù99.35¤¸.......«ùªÑ¤ñ¨Ò53.07%

¤d±i«ùªÑ¦bW37©P.¤W¶g¦¬½L§¡»ù64.26¤¸..«ùªÑ¤ñ¨Ò56.17%

¥[¤W8¤ë¥÷¸³¨ÆªøÃö«Y¤H¼W¥[«ùªÑ310±i...§¡»ù¦b73.6¤¸ªþªñ..

·í°ò¥»­±¶V¨Ó¶V¦n..¤jªÑªF­Ì³£¦A¥[½X...¿ï¾Ü½æªÑ²¼ªº¸Ü...³oÅ޿觹¥þ¤£¹ï...

¥Ø«eÀ£½L¦Ü60¤¸ªþªñ»ù¦ì·¥¨ã§ë¸ê»ù­È...

¥H¤W~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/19 ¤W¤È 10:27:45²Ä1006½g¦^À³
³Ì·s¬d¸ß¸ê®Æ..

8¤ë¥÷¸³¨ÆªøÃö«Y¤H«ùªÑ¼W¥[310±i.§¡»ù¬ù73.6¤¸¥ª¥k..

ªø´Á§ë¸ê¾Ô¤Í­Ì...¥Ø«e»ù¦ì§ë¸ê»ù­È¬Û·í¤j...«Øij¥iÀH¤jªÑªF¦A¥[½X...

¸Ô²Ó¸ê®Æ¥i¬d¸ßªÑ¥«Æ[´ú¯¸..

¥H¤W~¨Ñ´¼¼z.µ½¨}ªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò~

·|­û:YOYO10140343µoªí®É¶¡:2018/9/19 ¤W¤È 10:17:18²Ä1005½g¦^À³
¤£ºÞ¬OIPO©Î²{¼W,³£¬O¤½¥q¶Ò¿úªº®É¶¡ÂI,¦b²{¼W®É¶¡ÂI,¤½¥q¬£·|¥Î®ø®§­±°µ¦h,¥]¬A±ÂÅv³£¬O¤@­Ó¤è¦V,¨Ì¦¹¤½¥qªº­·®æ,¤£¯àÁ¿¤Ó¦h,¦b²{¼W«e¦³¾÷·|µ¹ªÑ¥Á­Ì¤@­Ó§Q¦h,²{¦b½æªÑªº¤H·í§Q¦h¤½§G¤@©w·|儍²´,¦Ü©ó§C»ù¶R¶iªº,¥i¥HÁÂÁ³̪ñ½æªÑµ¹§A­Ìªº.³Ì«á,ÁÙ¬O¤£¯àÁ¿¤Ó¦h.
·|­û:²q·Q10136148µoªí®É¶¡:2018/9/17 ¤U¤È 03:34:56²Ä1004½g¦^À³
¹ï2018 Á{®ÉªÑªF·|ªº«ä¦Ò

. ¤j®a¦³¨S¦³·Q¹L : ¶}·|®É¶¡¬°¦ó¿ï¦b 2018¦~©³ ³o­Ó®ÉÂI?

. °²­Y¬O¨Mij¨ì°ê¥~±¾µP , ¬O§_¤]·|¤@¨Ö°Q½×¼W¸ê®× , ¥H¦]À³±¾µP«eªÅµ¡´Áªº¬ãµo¤ä¥X ? ­Y¨S°Q½×¼W¸ê , ½²±Ð±Â¬O¥´¬Æ»ò¼Ëªººâ½L ?

. ¿Å½Ñ¸gÅç , ½²±Ð±Â°µ¨Æ³£¬O¦³­p¹ºªº , ³o¦¸±¾µP¦Ò¼{ªº­«ÂI¬O¬Æ»ò ?

.. ±¾µP¤é´Áªº¿ï¾Ü ·|¿ï¦bSND-13¸Ñª¼¥H«á¶Ü ? °²¦p¸Ñª¼¹LÃö , IPO·|§_°ª»ù±¾µP ? ( ¤pªº¦b·Q:¬O§_¸Ñª¼¦¨¥\ , ´N·|ÀH§Y±ÂÅv ? )

.. ÃB©w¸ê¥»ÃB·|¦b2»õªÑ¥H¤º¶Ü (SYNEURX LIFESCIENCE US, INCªºÃB©w¸ê¥»ÃB¥Ø«e¬O2»õªÑ ) ? ¹ê¦¬¸ê¥»ÃB·|¦b³o­ÓÃB«×¤ºÅÜ°Ê¶Ü ?

. ½²±Ð±Â»¡¤£­n°Q½× , ¤pªº·|³QºVÀY , ½Ð¤j®a­ì½Ì¤pªºµL¤ß¤§Á|

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a !

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/17 ¤W¤È 08:31:07²Ä1003½g¦^À³
¥¼Àò§Q¥ÍÂå±¾µPAªÑ ÀÀÃP¸j

2018-09-17 00:24¸gÀÙ¤é³ø °OªÌ¶À¤å©_/¥x¥_³ø¾É

money.udn.com/money/story/10161/3371270

¦b®Éµ{¤W¡A±M®a¤ÀªR¡A¤W®üAªÑ­n¶}©ñ¥¼Àò§Qªº¥Í§Þ¥ø·~±¾µP¡A¤´¨ü¨ì¤j³°¡mÃÒ¨éªk¡nªº³W©w©Ò­­¨î¡C®Ú¾Ú¤j³°¡mÃÒ¨éªk¡n²Ä13±ø³W©w¡A¦b¤j³°±¾µPªº¥ø·~¶·¡u¨ã¦³«ùÄò¬Õ§Q¯à¤O¡A°]°Èª¬ªp¨}¦n¡v¡A¦]¦¹¡AÃҺʷ|¦^À³¥þ°ê¬F¨óªº¤W­z¡u´£®×¡v®É¡A¤~¯S§O±j½Õ¡u¨Ìªk¡v¤ä«ù¡A§Y¨Ï©ú¦~ªk«ß¸Ñ¸T¡A¥ø·~­n¦b¤j³°AªÑ±¾µP¤]¶·±Æ¶¤¡A­nªï¨Ó­º®a¥¼Àò§Q¥Í§Þ¤½¥q¤W¥«ÁÙ­nµ¥µ¥¡C

ªþµù :

¥xÆW³Ì§Cµ|­tµ|ªk

¤¤°ê¤j³°±¾µP , §K¼x³Ì§Cµ|­t

´ä ¬ü±¾µP , ¦~Àò§Q¶W¹L670¸U(?)(ª÷ÃB©Î¦³¥X¤J)¥x¹ôªÌ , ú20%³Ì§Cµ|­t

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/16 ¤W¤È 11:46:47²Ä1002½g¦^À³
¥þ²yºZ¾PÃÄTOP10ªº¶Â®Øĵ§i²­z

¨Ó·½¡GÃÄ´ç ¡@2018-09-16

§@ªÌ¡G°û¤¼

med.sina.com/article_detail_103_2_52747.html

¶Â®Øĵ§i(black box warning)

©Ò¿×ªº¶Â®Øĵ§i¬O¬ü°êFDA¹ï¤W¥«ÃĪ«±Ä¨úªº¤@ºØ³ÌÄY­«ªºÄµ§i§Î¦¡¡A¥X²{¦b»¡©ú®Ñªº³Ì«eºÝ¡A¥Î¥[²Ê¥[¶ÂªºÃä®Ø¨ÓÅã¥Ü¡A¦®¦b¥H¿ô¥Øªº¼Ð»x´£¿ôÂå®v©M±wªÌ¦bÃĪ«¨Ï¥Î¹Lµ{¤¤¼ç¦bªº­«¤j¦w¥þ©Ê°ÝÃD¡A§Æ±æÂå®v©M±wªÌ¯à°÷¹ï¸ÓÃþÃÄ«~ªº­·ÀI¦³¨¬°÷ªº¤F¸Ñ¥H«K¥¿½Tµû¦ôÀò¯q/­·ÀI¡C

¥þ²yºZ¾PÃÄTOP10ªº¶Â®Øĵ§i

EvaluatePharmaµo¥¬ªº³ø§i¡mEP Vantage 2018 Preview¡n¤¤¡A¹ï2018¦~¥þ²y³ÌºZ¾Pªº10´ÚÃĪ«¶i¦æ¤F¹w´ú¡A³q¹L½Õ¬ã¡Aµo²{10´ÚÃĪ«¤¤¦³8´Ú»¡©ú®Ñ¤¤¦³¶Â®Øĵ§i¡C¦ý¤W¥[¤W¶Â®Øĵ§i¡A¨Ã¤£·N¨ýµÛÃĪ«¡§¥´¤J§N®c¡¨¡A¦Ó¬O¬°¤F´£¿ôÂå®v©M±wªÌÀ³¦b¦X¾Aªº¤H¸s¤¤¨Ï¥ÎÃĪ«¡A¨Ã¥BÄY®æ«ö·Ó±ÀÂ˪º¥Îªk¥Î¶q¶i¦æ¥ÎÃÄ¡AÁקK¶W½d³ò¶W¾¯¶q¥ÎÃÄ¡C

TOP1ªü¹F¤ì³æ§Ü

³q¥Î¦WºÙ¡Gªü¹F¤ì³æ§Üª`®g²G

°Ó«~¦W¡GHumira(­×¬ü¼Ö)

¬ãµo¥ø·~¡G¦ã§Bºû

2018¦~¾P°â¹w´ú¡G200»õ¬ü¤¸

FDA¹ï¨ä»¡©ú®Ñ¼W¥[¤F¨â¶µ¶Â®Øĵ§i¤º®e¡A¤À§O¬°ÄY­«·P¬V©M´c©Ê¸~½F

´£¿ô±wªÌ¸ÓÃĦ³¼W¥[ÄY­«·P¬Vªº­·ÀI¡A¦pµ²®Ö¡B²Óµß©Ê±Ñ¦å¯g¡B«Iŧ©Ê¯uµß·P¬V(¦p²Õ´­M¼ßµß¯f)µ¥¡A¨Ã¥B¦b¨àµ£©M«C¤Ö¦~±wªÌ¤¤´¿³ø¾É¥X²{²O¤Ú½F©M¨ä¥L­P©Rªº´c©Ê¸~½F¡C

Áö¦p¦¹ ¨ÌµM±Æ¦W²Ä¤@ ¦~½æ©Î¶W200»õ¬ü¤¸

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/13 ¤W¤È 11:15:03²Ä1001½g¦^À³
Ä~°ò¨È³sÄò6¤äº¦°±«á...

¤µ¤éÂà¥Ñ¯E¹©/¶h¹F/¶¶ÃÄ...µ¥·sÃÄÃþªÑ°ª±¾º¦°±Âê³æ...

ªñ´X­Ó¤ë³Ì®zªº¤¤¸Î¥Ø«e½L¤¤¤]¤jº¦ªñ6%...

--------------------------------------------------------------

¥xÆW¥Í§ÞÃþªÑ¤U¶^ªi¬qªñ3¦~..

¤µ¦~¥Í§ÞÃþªÑ½Âàªø´Á5-10¦~¤j¦hÀYÁͶեi¦n¦n§â´¤...

--------------------------------------------------------------

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò.

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/9/12 ¤U¤È 01:25:54²Ä1000½g¦^À³
2016¦~1/29¤é ¤ß®®ªÑ»ù265¤¸°ªÂI¦Ü¤µ¤é2018¦~9/12...ªÑ»ù64¤¸¤W¤U...

----------------------------------------------------------------------------------------------------

¥H¤µ¦~ªº°ò¥»­±¨Ó¬Ý...

1.¼~Æ{¯g³o°ê»Ú©Êªº·sÃĤµ¦~FDA®Ö­ã¶i¤J¤T´Á...

2.«e¤Ñ(9/10)¤½¥q¨u¨£µo·s»D½Z..«Å¥¬¨äSNS¨t¦C²£«~¤é«e¤ÀÀò¤¤µØ¥Á°ê¸gÀÙ³¡´¼¼z°]²£§½¡B

¬ü°ê±M§Q°Ó¼Ð§½¤§±M§Q®Ö­ã³qª¾..¥¼¨Ó±Nµo®iSNS¨t¦C²£«~..¶W¯Å¾Ç¦WÃÄ(Supergenerics; Hybrid Generics)¡C

----------------------------------------------------------------------------------------------------

¤ß®®¦Ü¤W¶g9/7¤éªº«ùªÑ¤À¯Å²Î­p¼Æ¦r..

¤d±i¥H¤W¤j¤á«ùªÑ¤ñ¨Ò¨Ó¨ì56.2%...¦A³Ð¤µ¦~·s°ª...

-----------------------------------------------------------------------------------------------------

°ò¥»­±¶V¨Ó¶V¦n..ªø´Á§ë¸ê..¥H¶g¬°³æ¦ì...¨é°ÓÀ£½L®É..ª÷¦r¶ð¦V¤U¶Rªk..¨C©P©T©w¥[½X...

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò~

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/4 ¤U¤È 01:04:54²Ä999½g¦^À³
kim ¥S

±z»¡±o·¥¬O

½²±Ð±Â¬O¤@­Ó·¥¬°§C½Õªº¦ÑÁó , ¨ì¥Ø«e¬°¤î , ¨Æ±¡¥¼¦¨¼ôµ´¤£ÅS¤f­·

Janssen ·|³o¼Ë´y­z , ·Q¥²¦³©Ò¥»

¦Ü©ó©M¤ß®®¦³µL±µÄ² , ·Q¥²¤]¬O¦³

¥u¬O¦³µL¦@ÃÑ , ©Îñ¸p·N¦V®Ñ¤§Ãþªº¤å¥ó , §Ú­ÌµLªk±oª¾

¤p§Ì·|°µ³o¼Ëªº²q´ú , ¬O¨Ì Janssen ²£«~½uªº¯S©Ê¨Ó¦Ò¼{ªº

Janssen ¦b«äı¥¢½Õ»â°ìªº¤@­Ó¤ë©M¤T­Ó¤ëªºªø®Ä¾¯ (Invega Sustenna ©M Invega Trinza )À³¬ORISPERDALÃþªº½wÄÀ¾¯ , ¥HªvÀø¥¿©Ê¯gª¬¬°¥D , ­t©Ê¯gª¬©Î¦³®ÄªG , »{ª¾¯Ê·l¥i¯à¨S¦³Àø®Ä

­Y»P SND-13 ¦X¨ÖªvÀø , ©Î¯àµo´§ 1 + 1 ¤j©óµ¥©ó 3 (¥¿©Ê¯gª¬ + ­t©Ê¯gª¬ + »{ª¾¯Ê·l )ªº±j¶Õ®ÄªG , ¹ï Janssen ©Î¦³¦pªê²KÁl¤§¥\

¦A´N MDD ©Î TRD ¨Ó»¡

¥H MDD ªº¤­¤j­±¦V¨Óµû¤ñ¤p§Ì©Òª¾¤½¥qªº²£«~½u---1.µ¹ÃĤè«K©Ê ; 2.½w¸Ñ§íÆ{ ; 3.°_®Ä³t«× ; 4.­°§C¦Û±þ·N©À ; 5. ¼W±j»{ª¾

Allergan ªº Rapastinel + AGN-241751 ( IV + ¤fªA ) ¨ã¦³ 1 , 2 , 3 , 5 ; 4 ÁÙ¦b¸ÕÅç

SAGE ªº ¤fªA SAGE-217 ¨ã¦³ 1 , 2 , 3 ; 4 , 5 ©Î¨SÀø®Ä

NEURORX ªº NRX-100 + NRX-101 ( IV + ¤fªA ) ¨ã¦³ 1 , 2 , 3 , 4 ; 5 ©Î¨SÀø®Ä

Janssen ªº»ó¼Q¾¯ Esketamine ¨ã¦³ 1 , 2 , 3 , 4 ; 5 ¨SÀø®Ä , ¦ý¦³¤£¯àªø¤[¨Ï¥Îªº°Æ§@¥Î

SNG-12 ¤fªA ¨ã¦³ 1 , 2 , 4 , 5 ; 3 ¨S§O¤H§Ö ( ¨â¤Ñ°_®Ä )

Àu¯ÊÂI¦h¦b³o¸Ì¤F , Janssen ¦³½Ö¥i¥H¦Ò¼{¦X§@

ÁöµM³ø¸ü Janssen ¦³·N»PAllergan µ²·ù

¦ý¬OAllergan ¥H¸g¦³¤FRapastinel ¦ó»ÝEsketamine

©Ò¥H

¦Ò¶q½Ñ¦h¦]¯À«á , Janssen ªº Esketamine + ¤ß®®ªº SNG-12 ©Î¥i¤­¶µ¥þ¯à

¦Ü©ó ¥¢´¼¯gªºÃÄ , ­Y¦³¦¨¥\ªÌ , §Ú·Q , À³·|¬O·m¤â³f

¤ß®®·|¤£·|Àò±oJanssen «C·ý , §Ú·Q¥u¬O»ù®æ°ÝÃD

­Ó¤H²q´ú

¥u­nSND-13 ²v¥ý¦¨¥\ , ¤ß®®¯¸¦b¥¨¤HªÓ»H¤W , ©Î«ü´Á¥i«Ý

¥«³õÄvª§ºA¶Õ¤@¤é¤d¨½ , ¤p§Ì¥u¦b³oÃä¦Ò¶qªº±ø¥ó , ·íµM¬O¬E¤@º|¸Uªº

¥u¯à·í°µ¯ù¾l¶º«áªº¸ÜÃD , ¤£¥i»{¯u¬Ý«Ý , §ó¤£¯à°µ¬°§ë¸ê¨Ì¾Ú

§Æ±æ¤ß®®Á{§É¶¶§Q , ¾¨¦­§¹¦¨

³Ì«á , ¤´¬O¦Ñ¸Ü¤@¥y

¦³½Ð¤j®a«ü¥¿«ü¾É¤Î¸É¥R

¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/4 ¤U¤È 01:00:32²Ä998½g¦^À³
¬ì¾Ç®aÄÄ©ú¤j¸£¤¤¯«¸g¤¸·s«¬§@¥Î¾÷¨î

¨Ó·½¡G ¥Íª«¨¦ ¡@2018-09-03

med.sina.com/article_detail_103_1_51965.html

¦P®É

ÁÂÁ¤p·ç¤jªº¤À¨É

·|­û:¤p·ç10140606µoªí®É¶¡:2018/9/4 ¤U¤È 12:50:58²Ä997½g¦^À³
¦U¦ì¤ß¤Í¤È¦w,

·PÁ²q·Q¤j«ùÄò¤À¨É®ø®§µ¹¤j®a¡A²{¦b´N¬OÀRÀRµ¥«ÝÁ{®ÉªÑªF·|¤F¡A

¬Ý¬Ý¤½¥q¨ì®É«Å¥¬ªº¶Ò¸ê¤è¦¡¡A¬O°ê¤º¼W¸ê¡B¬¢¯S©w¤H¨p¶Ò¡B©Î¬O®ü¥~µo¦æ¦s°U¾ÌÃÒ¡A

©Î¬Æ¦Ü¬O±q»OÆW¤U¥«¡A§ï¦Ü¬ü°ê©Î­»´ä¤W¥«¡A

¬Ý¬Ý¦P¼Ë¨S¦³À禬ªºSage¥Ø«e¥«­È¶W¹L2000»õ¤¸¥x¹ô¡A¤ß®®³s100»õ¤¸³£¤£¨ì¡A

©ú©ú¬ãµoªº²£«~©M¶i«×³£¨S¦³¤ñ¸û®t¡A¦ý¥«­È´N¬O®t¦p¦¹¤j¡A

µL½×¤½¥q¦p¦ó¨M©w¡A¤p§Ì³£¬Û«H½²¸³·|¬°¤j®a¿ï¾Ü¤@­Ó¬Û¹ï¦nªº¤è®×¡A

¤£¹L²¦³º¥xÆW¸ê¥»¥«³õ©M§ë¸ê°é³£¤£¼ô±x¥Í§Þ²£·~¡A

¤p§ÌÁÙ¬O«Ü»{¦P¦b»OÆW¤U¥«¡A§ï¥h¬ü°ê¤W¥«¡A

Á`¤§¡A¤ß®®¥[ªo~~

·|­û:kim10134548µoªí®É¶¡:2018/9/4 ¤W¤È 09:52:44²Ä996½g¦^À³
²q·Q ¤j­ô

¬Ý¨ì±z´£¨Ñ³o»ò¦h§Ú­Ì¤ß®®¤½¥q¬ãµo²£«~ªº¯S¦â¡A

¬O¦h»ò²Å¦X Janssenªº»Ý¨D©Mµo®i¤è¦V¡A

´N¬O¤£ª¾¹D©¼¦¹Âù¤è¡A¦³µL·f¤W½u¥H¤Î¦X§@ªº¥i¯à¡H

§_«h¤j®a¥ú¬O¦b³o¸Ì¤À¨É©Î°Q½×¡A¯uªºµLÀÙ©ó¨Æ¡A

¥u¯àªÅÅw³ß¤@³õÅo¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/3 ¤U¤È 07:32:28²Ä995½g¦^À³

J&J ªº Janssen ¥¦ºô­¶¸Ì¦³

Our Areas of Interest for Collaboration

¨ä¤¤ªº¨â­Ó

Depression and Treatment-Resistant Depression¶µ¥Ø¸Ìªº

. Phase 2 and later-stage opportunities with defined mechanism of action and superior efficacy over standard of care

www.janssen.com/neuroscience/mood-disorders

©M

chizophrenia »â°ìªº

Novel Therapies in Phase 2b or Later for Symptomatic Treatment of the Underlying Symptoms of Schizophrenia with Special Emphasis on Treatment of Cognitive Impairment and Negative Symptoms.

www.janssen.com/neuroscience/schizophrenia

§Ú­Ì¤w½Í¹L

¦b¤ß®®ªº²£«~½u¸Ì , ´N³Ñ¥¢´¼¯g»â°ìÁÙ¥¼»P Janssen ³sµ²

Janssen ªººô­¶¬O³o¼Ëªº

»â°ì : Alzheimer¡¦s Disease and Neurodegenerative Disorders

¶µ¥Ø : Symptomatic Treatment of Cognitive Impairment and Neuropsychiatric Conditions

¼gµÛ

. Novel agents with Phase 2 proof-of- concept in neuropsychiatric symptoms or neuropsychiatric symptoms with cognitive impairment that exhibit superior efficacy to standard of care (e.g., antipsychotics, acetylcholinesterase inhibitors) as monotherapy or adjunctive therapy with synergistic efficacy.

www.janssen.com/neuroscience/alzheimers

¬Ý¬Ý³o»â°ì Janssen ¹ï SND-14 ¦³¨S¦³°w¹ï©Ê?

. Novel agents

. Phase 2 proof-of- concept

. neuropsychiatric symptoms with cognitive impairment

. exhibit superior efficacy to standard of care

. monotherapy or adjunctive therapy with synergistic efficacy.

²{¦æ¨Ï¥ÎªºÃĪ«¦³ : ( µø¬°standard of care )

¤@¡B¤AñQÁxÆP酶§í¨î¾¯ ¡]Acetyl-cholinesterase inhibitor¡^: ¥Ø«e¥«­±¤WFDA®Ö­ãªº¥D­n¨Ï¥ÎÃĪ«¦³: Donepezil¡B Rivastigmine¡B Galantamine¡C

¤G¡BNMDA¨üÅé«ú§Ü¾¯(NMDA natagonist) : ¹ï¤¤­««×ªü¯÷®üÀq¯g±wªÌ¸û¬°¦³®Ä¡CÃĪ«¦³ : Memantine

¦Ó

SND-14 ¸ÕÅç©Ò¥Îªº AChEIs ( acetylcholinesterase inhibitors ) ´N¬O¤W­zªº¤TºØÃĪ«

• Donepezil

• Rivastigmine

• Galantamine

³¡¤À±wªÌ¨Ï¥Î , ³¡¤À±wªÌ¨S¨Ï¥Î , ©Ò¥HÀ³¥i¬Ý¦¨ : ³¡¤À¬° monotherapy , ³¡¤À¬° adjunctive therapy

©Ò¥H

¤ß®®¤T¤j»â°ìªº²£«~½u , °µ¹LÁ{§É¤G´Áªº , ¦ü¥G³£©MJanssen©Ò±ý¦X§@¹ï¶Hªº´y­z¬Ûªñ

¨s³º¤T­Ó³£¬O¥©¦X? ÁÙ¬O¦U¨ã°w¹ï©Ê?

??? ºÃ°Ý¦b¤ß¤¤§r!

¦³½Ð¤j®a«ü¥¿

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/9/3 ¤W¤È 06:52:39²Ä994½g¦^À³
¥Í§Þµ¦²¤·|ij ¤­»â°ì»EµJ

2018-09-03 00:35¸gÀÙ¤é³ø °OªÌ¶À¤å©_/¥x¥_³ø¾É

udn.com/news/story/7485/3344930?from=udn_ch2cate6644sub7485_pulldownmenu

­È±o¤@´£ªº¬O¡A³Ìªñ±N­n¼i·s¡B­t³d¥ÍÂå²£·~±À°Êªº¬ì§Þ³¡¬F°È¦¸ªøÁ¹FÙy¡A¦]¤H¨Æµ{§Ç©|¥¼§¹¦¨¡A¬O§_¨Ó±o¤Î»P·|¡A¤]³Æ¨üÆf¥Ø¡C¥t¥~¡A¦h¦~¨Ó§¡°Ñ»PBTC¨Ãµ¹¤©«Ø¨¥ªº¤¤¬ã°|°|¤h³¯¨}³Õ¡A¤µ¦~½T©w±N¤£¦^¥x»P·|¡C

ĬªÚ¼y¦¸ªø¤~·í¤@¦~¦h¡Aµ²§ô­É½Õ«á­u¬ü¥ðªø°²¡A¿ò¯Ê¤w¸g½T©w¥Ñ¦¨¤j¤fµÄÂå¾Ç¬ã¨s©Ò¯S¸u±Ð±ÂÁ¹FÙy±µ¥ô¡A·~¬É´Á«Ý¡AÁ¹FÙy­Y±µ¤U¥ÍÂå²£·~³Ð·s±À°Ê¤è®×°õ¦æ¤¤¤ß°õ¦æªø¤@¾«á¡A¯à¾á·í±À°Ê²£·~ªº¤j¥ô¡A­Y¯à°Ñ¥[¦¹¦¸¦æ¬F°|BTC·|ij«h§ó¯à²z¸Ñ²£·~´Á«Ý¡C

ªþµù¡G

Á¹FÙy±Ð±Â¤]»P¤ß®®¦³±M§Q¦X§@²W·½

United States Patent 9,724,279

August 8, 2017

Core-shell particles, preparation process thereof, and composition containing the same

Inventors: Shieh; Dar-Bin (Tainan, TW)

Assignee: SYNEURX INTERNATIONAL CORP. (Taipei, TW)

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/30 ¤U¤È 04:16:05²Ä993½g¦^À³
»D·s½à

Ketamine Nasal Spray Relieves Suicidal Thoughts, but Doctors Worry About Abuse Risk

´âÓi଻óµÄ¼QÃú½w¸Ñ¤F¦Û±þ©ÀÀY¡A¦ýÂå¥Í¾á¤ßÀݥέ·ÀI

Ed Cara

4/17/18 5:30pm

gizmodo.com/ketamine-nasal-spray-relieves-suicidal-thoughts-but-do-1825326772

......

µM¦Ó¡A´âÓiତ]¤£¬O§íÆ{¯gªº¯«©_ÃĪ«¡C¤j¬ù50¢H¦Ü60¢Hªº±wªÌ¹ï¦¹¦³¤ÏÀ³¡A§Y¨Ï¦b³o¨Ç±wªÌ¤¤¡A¨ä¿W¯Sªº®ÄªG¤]¤£·|«ù¤[¡C¦b¥Ø«eªº¬ã¨s¤¤¡AÁöµM¨Ï¥Îesketamineªº±wªÌ·Pı¤ñ°_ªì®É§ó¤Ö§íÆ{©M¦Û±þ¡A¦ý¦b24¤Ñµ²§ô®É¡A¥L­Ì³Ì²×¨Ã¨S¦³¤ñ(¦w¼¢¾¯+¼Ð·ÇªvÀø)²Õ§ó¦n¡C¬ã¨s¤H­û»¡¡A¬ã¨s¼Ë¥»¤¤¨S¦³´âÓiନ̿઺¸ñ¶H¡C

½s¿è§@ªÌ¨Ã¨S¦³§¹¥þÃö³¬´âÓiଡA¦Ó¬O´£­Ò¦bÀݥΤ§«e¥ý«Ø¥ß¤@­Ó¦w¥þªvÀø®Ø¬[¡C¥L­Ì«Øij¡A¥i¯à­n¨DÂå¥Í©MÂå°|¥u¤¹³\±wªÌ¦b¥L­Ìªºª½±µºÊ·þ¤U¨Ï¥Î¦ã´âÓiଡC©ÎªÌ¡AÃþ¦ü©ó²{¦bªºªü¤ùÃþÃĪ«³B¤è¡A±wªÌ¥i¥H¦b¥þ°ê½d³òªºµn°O³B°O¿ý¥L­Ìªº´âÓiଳB¤è¡A¥H¨¾¤î¤H­Ì³X°Ý¦h¦WÂå¥Í¥HÀò±o§ó¦h¾¯¶q¡C

......

³o¼Ëªºesketamine·|¦³°Ó·~»ù­È¶Ü? ªp¥BÁÙ­n¦Ò¼{»H¯Ö®e¶qÅܤpªº°Æ§@¥Î

µM©Î³\ J&J ¤w¸g¦³¸¡®×¤F?!

§g¤£¨£

J&J ªº Janssen ¥¦ºô­¶¸Ì¦³

Our Areas of Interest for Collaboration

¦b Mood Disorders »â°ìªº Depression and Treatment-Resistant Depression ¶µ¥Ø¸Ì

www.janssen.com/neuroscience/mood-disorders

¼gµÛ

. Phase 2 and later-stage opportunities with defined mechanism of action and superior efficacy over standard of care

¬Ý¬ÝSNG-12 ²Å¦X¶Ü?

. Phase 2 and later-stage

. defined mechanism of action

. superior efficacy over standard of care

SNG-12 ©Ò¹ï·Óªº standard of care ÃĪ« , ¬O±`¥ÎªºÄÝ©óSSRIs Ãþªº citalopram

³o¼Ë´N¥i¥H

esketamine(¦bÂå®vºÊ·þ¶È¼Q1¦¸) + (º¸«á)¤fªASNG-12

¨Ó½w¸Ñ§íÆ{¤Î¦Û±þ·N©À

³o¬O¤pªº¦Û¤v·Qªº , ¬O±qµïµ·°¨¸ñ¤¤ªº¶ÃÂIÀpÀmÃÐ

µ²ªG¦p¦ó? ´N«Ý®É¶¡¨Ó´¦¾å¤F!

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/30 ¤W¤È 10:45:49²Ä992½g¦^À³
NaBen ªº°Ó¼Ð¥Ó½Ð¤F!

www.trademarks411.com/search?o=SyneuRx+International+%28Taiwan%29+Corp.&option=srearch_3&sub_option=sub_srearch_1

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/30 ¤W¤È 10:39:37²Ä991½g¦^À³
³Ì·s¬ã¨s¡G¤ßŦ°·±d¶¼­¹¥i¯à¸ò¥H«e»{¬°ªº¤£¤@¼Ë

¨Ó·½¡G±d°··sµø³¥ ¡@2018-08-30

med.sina.com/article_detail_103_1_51719.html

³o¨Çµ²ªGªí©ú¡A¬°¤F¤ß¦åºÞ°·±dªº¥Øªº¡A¤H­ÌÀ³¸Ó­­¨îÄá¤Jªººë»sºÒ¤ô¤Æ¦Xª«ªº¼Æ¶q¡A¦ý¥i¥H±N¨Å»s«~©M¥¼¥[¤uªº¦×Ãþ§@¬°°·±d¶¼­¹ªº¤@³¡¤À¡C

§Ú­Ìªº¬ã¨sµ²ªGªí©ú¨Å»s«~©M¦×Ãþ¦³¯q©ó¤ßŦ°·±d©Mªø¹Ø¡A³o»P¥Ø«eªº¶¼­¹«Øij¤£¦P¡C

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/8/28 ¤W¤È 10:51:47²Ä990½g¦^À³
·|­û¡G³\¤j10137169 µoªí®É¶¡:2018/8/26 ¤W¤È 08:45:39²Ä 987 ½g¦^À³

°·O³o­Ó§ë¸ê¤½¥q¤W¥b¦~ÁÈ0.29¤¸

ÁÙ¦hÁ«²Ä¤@©u±Ò°Ê¦L¶r¾÷¥ýÁÈ0.23¤¸¹Ô­Ó©³

²Ä¤G©u¤Ö¤F¦L¶r¾÷°]³ø´N¬Û§Î¥¢¦â.

¥Ø«e¨Ó¬Ý¦pªG­n¹F¦¨¬Y­ÓÀò§Q¥Ø¼Ð

³o¥x¦L¶r¾÷¥i¯à­n¶}º¡²Ä¤T©u¬Æ¦Ü¨ì²Ä¥|©u...

©Ò¥H¬Ý»ù®æ§Ú¤]¦³¨Ç¾á¤ß.

---------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------

³\¤j¤j...¦­...¨Ì·Ó³\¤j±z8/26´£¨ì°·OªººÃ¼{...²Ä¤@©u°·OÄÀ¥X³¡¤À«ùªÑÀò§Q...

¦ý¹ï·Ó¤ß®®²Ä¤@©uªÑ»ù...

±q1/2ªº¦¬½L»ù50.29¤¸ ²Ä¤@©u3/31µ²§ô ¦¬½L»ù73.1¤¸..ªÑ»ù¬O¤Wº¦¤F45%...

°ò¥»­±«ùÄò¦V¤W...·sÃļƾڻP¶i«×«ùÄò¦V¤W...

ªÑ»ù²×¨s·|¦^Âk°ò¥»­±...ªÑ»ù¦ÛµM·|§e²{À³¦³ªº»ù­È.....

¥H¤W²LÁ¡¤§¨£...¨Ñ´¼¼z.µ½¨}ªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò...

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/26 ¤U¤È 12:02:52²Ä989½g¦^À³
½w¸Ñªü¯÷®üÀq¯f¼Æ¦rÂåÀø²£«~ÀòFDA¬ð¯}©Ê³]³Æ(Breakthrough Device designation¡^(BDD)»{©w

¨Ó·½¡GÃÄ©ú±d¼w¡@2018-08-26

med.sina.com/article_detail_100_2_51433.html

Dthera Sciences¬O¤@®a±Mª`©ó¶}µo¯«¸g°h¦æ©Ê¯e¯f¼Æ¦rÂåÀø²£«~ªº¤½¥q¡Aªñ¤é¸Ó¤½¥q«Å¥¬¨ä¦b¬ã²£«~DTHR-ALZÀò±oFDA±Â¤©ªº¬ð¯}©Ê³]³Æ»{©w¡]Breakthrough Device designation¡^¡A°w¹ïªº¾AÀ³¯g¬O¡§½w¸Ñªü¯÷®üÀq¯fÃþ¯«¸g»{ª¾»Ùꪺ¿E°Ê©M§íÆ{¯gª¬¡¨ ¡C¾Ú±x¡ADthera Sciences¬O²Ä¤G®aÀò±oFDA¬ð¯}©Ê³]³Æ»{©wªº¼Æ¦rÂåÀø¤½¥q¡C¦pªGÀò±o§å­ã¡ADTHR-ALZ±N¦¨¬°ªü¯÷®üÀq¯f¯gª¬ªº²Ä¤@ºØ «DÃĪ«³B¤è ªvÀø¤èªk¡C

DTHR-ALZ¬O¤@ºØ³B¤è¼Æ¦rÂåÀø²£«~¡A¥¦³q¹L¦^¾ÐÀøªk¡]Reminiscence Therapy¡^ªvÀøªü¯÷®üÀq¯f¡C¸Ó³]³Æ±N¨Ï¥Î¤H¤u´¼¯àºâªk¡A°ò©ó±wªÌªº¦UºØ¥Íª«¤ÏõX¨Ó¦Û°ÊÀu¤ÆªvÀø¡C®Ú¾Úªü¯÷®üÀq¯f¨ó·|¤¶²Ð¡A¦^¾ÐÀøªk¬O¤@ºØ°ò©óÃÒ¾Úªº¤ß²zªÀ·|¤z¹w¤â¬q¡A¤w¸g¦bÁ{§É¸ÕÅ礤ÃÒ©ú¥i¥H§ïµ½ªü¯÷®üÀq¯fªº¯gª¬¡A

¦ý¥Ñ©ó»Ý­nÂå¥Í¤j¶qªº®É¶¡©M¸ê·½ªº§ë¤J¡A¥Ø«e³oºØÀøªkªº¨Ï¥Î¨ü¨ì­­¨î¡C

DTHR-ALZ¦³±æ´£¨Ñ°ªÀW²v¡B¤@­P©Ê©M­ÓÅé¤Æªº¦^¾ÐÀøªk¡A¦P®É»Ý­n³Ì¤Öªº®É¶¡©M¸ê·½§ë¤J¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/26 ¤W¤È 10:23:01²Ä988½g¦^À³
³\¤j¤j ±z¦n!

°·Oªº¨Mµ¦ , §Ú­ÌµLªk¸m³ñ

»·¨£©Îµuµø , §Ú­Ì¤]µLªkµû½× ,¤p§Ìªº·Qªk´N¬OÀH¥¦¥h½æ , ¥«³õ©Î¦³ÃѳfªÌ

¦Ü©ó±z´£ªº¨é°Ó ½Ð®¤¤p§ÌµL¯à , ¤¸¤jOO¤§©Ò¥H¦³¿ìªk²q , ¬O¦]¬°¦³°]³øªº¤½¥¬

ÁÂÁ±z!

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:³\¤j10137169µoªí®É¶¡:2018/8/26 ¤W¤È 08:45:39²Ä987½g¦^À³
²q¤j~

¦n¤[¤£¨£,¤p§Ì¸ò±z°Ý¦w!

°·¨È³o­Ó§ë¸ê¤½¥q¤W¥b¦~ÁÈ0.29¤¸

ÁÙ¦hÁ«²Ä¤@©u±Ò°Ê¦L¶r¾÷¥ýÁÈ0.23¤¸¹Ô­Ó©³

²Ä¤G©u¤Ö¤F¦L¶r¾÷°]³ø´N¬Û§Î¥¢¦â.

¥Ø«e¨Ó¬Ý¦pªG­n¹F¦¨¬Y­ÓÀò§Q¥Ø¼Ð

³o¥x¦L¶r¾÷¥i¯à­n¶}º¡²Ä¤T©u¬Æ¦Ü¨ì²Ä¥|©u...

©Ò¥H¬Ý»ù®æ§Ú¤]¦³¨Ç¾á¤ß.

²q¤j~

½Ð±Ð±z´X­Ó¤p°ÝÃD

´I¨¹¤j¦w,´I¨¹¥Á¥Í,¤¸¤jªQ¤s,¸s¯q¥j«F,¸s¯q·s¦Ë,²Î¤@·s¦Ë

³o´X®a劵°Ó¬O¦ó¤è¯«¸t

Àµ½Ð²q¤j©ú¥Ü

ÁÂÁÂ.

·|­û:seniorbbs10144999µoªí®É¶¡:2018/8/24 ¤U¤È 09:37:35²Ä986½g¦^À³
³Ìªñ¤@­Ó¤ë¨Ó¤¸¤jÂù©M¤S¦b¥X³f¤F......
·|­û:²q·Q10136148µoªí®É¶¡:2018/8/24 ¤U¤È 01:57:06²Ä985½g¦^À³
­É¥Î¤Ñ©R¤jªº¶K¤å

°ê®a¯Å¥Í§Þ°òª÷ ¨H§Ó¶©¾Þ½L

60»õ§Y±N¤J¥«¡C

money.udn.com/money/story/10161/3327086

®¥³ß

¸³¨Æªø±iÂE¤¯¥ý¥Í

¤]´¿¬°¤ß®®¸³¨Æ

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/21 ¤U¤È 07:36:45²Ä984½g¦^À³
FDA¡Gªüº¸¯ý®üÀq¯g¢»´Á¦b¬ãÃĪ«¤@Äý

¨Ó·½¡GCPhI»sÃĦb½u¡@2018-08-21

§@ªÌ¡GW&D

med.sina.com/article_detail_103_2_51125.html

Àò±oFDA§Ö³t¼f§å³q¹Dªº³B©ó¢»´ÁÁ{§É¸ÕÅ礤ªí²{Àu²§ªºÃĪ«¡C

1. Biogen»PNeurimmuneÁp¦X¶}µoªº³æ§Ü Aducanumab

2. Eisai©MBiogenÁp¦X¶}µoªº¤p¤À¤lÃĪ«Elenbecestat

3. Cognition Therapeutics¤½¥q¶}µoªº¤p¤À¤lÃĪ« CT1812 ( Elayta )

4. Novartis©MAmgenÁp¦X¶}µo¤p¤À¤lBACE§í¨î¾¯ AMG-520

5. vTv Therapeutics¤½¥q¶}µoªº Azeliragon , 2018¦~4¤ë¢»´ÁÁ{§É¸ÕÅç¨Ã¤£²z·Q¡A¥Ø«e¸Ó¤½¥q¤w¼È°±Á{§É¬ã¨s

6. Chugai Pharmaceutical©MGenentech¶}µoªº³æ§Ü Crenezumab

7. Transition Therapeutics©MElanÁp¦X¶}µoªºÁÞÃþÃĪ« ELND-005

8. BioHaven Pharmaceutical¤½¥q¶}µoªº Trigriluzole , 2017¦~10¤ëªvÀø¹B°Ê¥¢½ÕªºÁ{§É¸ÕÅ祢±Ñ¡C

³o 8 ÀɸÕÅçÃÄ´X¥G©M£]¾ý¯»¼Ë³J¥Õ¦³Ãö , ¬J»P£]¾ý¯»¼Ë³J¥Õ¬ÛÃö Àø®Ä¦n¤£¦n? ¤pªºµL±qµû½×

¤£¹LÅý¤pªº³Ì·P¿³½ìªº¬O CT1812 ( Elayta )

­Ë¤£¬O¦]¬°¥¦ªºÀø®Ä¦nÃa (Àø®Ä¦n¤£¦n? ²{¦b¥i¯àÁٽͤ£¤W)

(¦bµ¹ÃÄ28¤Ñµ²§ô®É¡AªvÀø²Õ©M¦w¼¢¾¯²Õªº»{ª¾µ²ªG¬Û¦ü(Cognitive outcomes were similar across treatment and placebo groups at the end of 28 days of dosing.)ªþµù: ¥i¯àªvÀø®É¶¡¤Óµu©Ò­P?)

( cogrx.com/2017/11/04/cognition-therapeutics-alzheimers-disease-candidate-ct1812-meets-phase-1b2a-study-objectives-well-tolerated-with-positive-influence-on-biomarkers-of-synapse-recovery/ )

¦Ó¬O¦]¬°¥¦±N°µ¤@­Ó¥vµL«e¨Òªº¸ÕÅçSPARC¡]COG0105¡^

SPARC¥Ñ¬ü°ê°ê¥ß½Ã¥Í¬ã¨s°|°ê®a¦ÑÄ֤Ƭã¨s©Ò´£¨Ñªº410¸U¬ü¤¸¸ê§U

¥¦©M­C¾|ªüº¸¯ý®üÀq¯f¬ã¨s¤¤¤ß¦X§@ , ¬O¥Î­C¾|SV2A PET·s«¬¬ðIJ¦¨¹³¾¯°µ¬ðIJ±K«×ªºÀË´ú

¦®¦b¤ñ¸û21¦Wªüº¸¯ý®üÀq¯f±wªÌªº¬ðIJ±K«×ÅܤơA³o¨Ç±wªÌ±N¨C¤Ñ¤@¦¸±µ¨üElayta©Î¦w¼¢¾¯ªvÀø24¶g

¨Ï¥ÎPET¦¨¹³±½´y¡A¦b°ò½u©Mµ¹ÃÄ12©M24¶g«áÀË©w¬ðIJ±K«×ªº

Áa¦V¬ã¨s

( cogrx.com/2018/06/18/cognition-therapeutics-initiates-nia-funded-sparc-study-of-elayta-to-assess-changes-in-synaptic-density-and-cognitive-performance-in-alzheimers-disease/ )

´NÅý§Ú­Ì´Á«Ý¥¦¦¨ªGªºµoªí

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

¬y¬P®±¤j

¹ï¤£°_! ´NÅý³o­Ó®ø®§¤î¦í¤£¦A½Í

¨Ã¦V¦Ñ¥v¤j¤j­Pºp

ÁÂÁ¤j®a!

·|­û:¬y¬P®±10022030µoªí®É¶¡:2018/8/21 ¤U¤È 05:35:29²Ä983½g¦^À³
­þ¦ì ¤ý´º¥¿? ¦Ñ¥v¬O¸³¨Æ­Ý°ÆÁ` ?

¬Ý¤£À´ ¬O³o·N«ä¶Ü

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/21 ¤U¤È 04:52:44²Ä982½g¦^À³
®¥¶P

¦Ñ¥v¤j¤j

ºaÁt ¤ß®®¥ÍÂ夽¥q ¸³¨Æ­Ý°ÆÁ`¸g²z

¤]½Ð¦Ñ¥v¤j¤j¦h¦hµo´§¤~´I¤­¨®ªº±M·~ , À°§U¤ß®®¥ÍÂ娫¦V±d²ø¤j¹D

§Ú­Ì³£±N»P¦³ºa²j °]´I5B

ÁÂÁ¦ѥv¤j¤j!

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/19 ¤U¤È 04:56:07²Ä981½g¦^À³
¤j®aÁÙ°O±oSAGE¤½¥qªvÀø²£«á¼~Æ{ (PPD)ªºSAGE-547 ( Brexanolone ) , ÁÙ¦³­««×¼~Æ{(MDD)ªºSAGE-217¶Ü?

¤p§Ì¤µ¤Ñ¦bµL·N¤¤ , ¬Ý¨ì¥¦­ÌªºÃÄ®ÄÀH®É¶¡ªº¤ÏÀ³¹Ï

¥Z¦b¸Ó¤½¥q¤µ¦~¤­¤ëµo¥¬ªº 2018 , Q 1 ©u³ø

investor.sagerx.com/static-files/aba670b3-69ad-4f5e-9053-b08cf9dc0ab9

P.10 & P.11

¦Ñ¥v¤j¤j´¿»¡ , ¦w¼¢¾¯ªº®ÄÀ³¤Ó°ª

·íªì¤pªº¤]¤£À´[¦w¼¢¾¯ªº®ÄÀ³¤Ó°ª] , ¨ì©³¦³¬Æ»ò¤£¦X²zªº²§¼Ë ?

¤µ¤Ñ¬Ý¤F³o­Ó¹Ï

ªì´Áªº¦w¼¢¾¯²Õªº^Àø®Ä^ , «ç»ò¤]·|¸òSAGE-217 ( 547 ) ²Õ´X¥G¦P¨B , ¤]¦³µÛ«D±`§Ö³tªº¤ÏÀ³?

¥t¥~

P.11 ¤]¦³Åý¤H°g´bªº¦a¤è , ¦w¼¢¾¯²Õ¦b§¹¦¨^ªvÀø^«á(14¤Ñ)¦±½u¨ÌµM©¹¤U¨« , ¨Ó¨ì²Ä6¶gªº´î»´50%

¦ÓP.10 ¥kÃäPlacebo 202C²Õ ªº¨«¶Õ¹Ï , ´N§ó¥O¤H©Q¦Þ¤F(¦b¨â¤Ñ³B´N¤wµ²§ô^ªvÀø^) !

???

¦Ñ¥v¤j¤j·íªìªººÃ´b , ¤pªº¦ü¦³©Ò·P!

¤S

¤pªº¦^ÀY¥h°l SAGE-217 ¤@´ÁªºÁ{§É¼Æ¾Ú

www.biologicalpsychiatryjournal.com/article/S0006-3223(17)30206-8/pdf

www.businesswire.com/news/home/20160607006570/en/Sage-Reports-Positive-Top-line-Results-Phase-1

µo²{¥¦ªºMTD ( maximum tolerated dose ) ¬O¥H¤¤«×¦Ü­««×ÂíÀRªº¤ñ¨Ò¨Ó­q©w

¬O§_´N¬O»¡SAGE-217¦³«Ü±jªºÂíÀR§@¥Î?

©Ò¥HSAGE¤½¥q¥u°µµu´ÁªºªvÀø (14¤Ñ) ¤£°µªø¤Ñ´ÁªvÀø ? ·íµM¤]¦³¯à¬O®Ú¾ÚÃĮĪº§PÂ_

¦P®É SAGE-217 ¤]¦b¶i¦æ§ï¶iºÎ¯vªºÁ{§É

investor.sagerx.com/static-files/aba670b3-69ad-4f5e-9053-b08cf9dc0ab9

P.13

³o¬O§_¤S¬OÂíÀRªº°Æ§@¥Î©Ò¤Þ­Pªºªþ±a®ÄªG©O?

¦ý¬OÂíÀR¤Ó²`¦³¨ä­·ÀI ½Ð°Ñ³o½g³ø¾É

µÎ¯vªvÀø­n¤p¤ß ±M®a¡G¹L¶q®£­P¦º

¤¤¥¡ªÀ2018/06/06 11:20

www.nownews.com/news/20180606/2766597

4.bp.blogspot.com/-wjDXaOopt-w/WCBxqPciL_I/AAAAAAAACnc/C6YRlBPuGcQd5FDJ6PVjQothW-NlJ0G0wCLcB/s640/%25E5%25A4%25A7%25E9%2599%25B8%25E8%25AC%259B%25E5%25AD%25B8.015.jpeg

³o¬O§_¤S·|­­¨î¥¦ªºÁ{§ÉÀ³¥Î ?

¤w¤WÆ[ÂI¯ÂÄݱÀºV²q´ú , ¦³½Ð¤j®a¸É¥R«ü¥¿

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

ªþµù :

SAGE-217¤G´ÁÁ{§É³ø§iºK­n :

www.biologicalpsychiatryjournal.com/article/S0006-3223(18)30435-9/fulltext

Results :

www.biologicalpsychiatryjournal.com/article/S0006-3223(18)30436-0/fulltext

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/17 ¤U¤È 04:53:02²Ä980½g¦^À³
¨â³õ·|ij

²Ä¤Q¤»©¡°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|

2018¦~8¤ë16-18¤é (½²±Ð±Â¬°8/18¤é¤U¤ÈCNS»â°ì¥D«ù¤H¤Î²Ä¤G³õ³ø§iªÌ)

¥Íª«¬ì§Þ§ë¸ê°ª®p·|

2018¦~10¤ë31¤é-11¤ë2¤é

liaw6575¤j¤j ½Ð¤j®a­Y¦³¦¬¶°¨ìºtÁ¿¿ý­µ©MºtÁ¿PPT , ·q½Ð¤£§[¤À¨É

¦P®É , liaw6575¤j¤j¤]©IÆ~¤½¥q , §Æ±æ¤½¥q¥i¥H¤½§i¬ÛÃö¤º®e©MPPT , Åý§ó¦h¤H¤F¸ÑCNS·sÃĬãµoªº²{ªp

¤pªº¤]¦³©Ò·P , ½Ð¤½¥q¦b¦X¥Gªk³Wªº­ì«h¤U , ºÉ¶q±NÁ{§É²{ªp§i¶D§ë¸ê¤H , ¦Ó¤£¬OÅý§ë¸ê¤HºN¶Â¦Û¤v§ä , ÁöµM¦³ªºªF¦è»{¯u¤@ÂI¥i¥H§ä¨ì , ¦ý¦³ªºªF¦è¨S¦³¤½¥qªº§iª¾ªº±¡ªp¤U , ¬O¤@©w§ä¤£¨ìªº

°ê¤º¦³¤½¥q³£¥i§i¶D§ë¸ê¤HÁ{§É¼Æ¾Ú²{ªp , ¤ß®®À³¤]¥i¥H¸ò¶i , ¥HÅW§ë¸ê¤H

¹ï¤£°_! ¤µ¤Ñ¤pªº·Pı¹³¤@­Ó³Q¤½¥q§N¸¨ªºOO

¸Ü»¡±o­«¤FÂI ¤]½Ð¤j®a­ì½Ì

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:seniorbbs10144999µoªí®É¶¡:2018/8/16 ¤U¤È 08:26:43²Ä979½g¦^À³
ÁÂÁ©¯¹B¤j¶}¥Ü¡C¡C¡C¡C §Æ±æ¤£¤[ªº±N¨Ó¡A¥i¥H¶}ªáµ²ªG¡C
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/8/16 ¤U¤È 01:37:24²Ä978½g¦^À³
seniorbbs¤j...

¦^ÅU¤@¤U...¤µ¦~5¤ë¥÷...¤ß®®ªº¤¤­««×¼~Æ{¯g·sÃÄ...FDA®Ö­ã¶i¤J¤T´Á...

¼~Æ{¯g·sÃĤ@¦~´N¦³116»õ¬ü¤¸¥H¤Wªº¥«³õ...

°ò¥»­±¬O¶V¨Ó¶V¦n...¤£¥Î¾á¤ß...

ªø´Á§ë¸ê...ªø½u¦hÀYÁͶÕ...À£¦^...«ùÄò¤À§å¥[½X...

·|­û:seniorbbs10144999µoªí®É¶¡:2018/8/16 ¤U¤È 01:08:58²Ä977½g¦^À³
§Æ±æ¯uªº¦³¦n®ø®§.....³Ìªñ¦^ÀɤF3X %...¯uªº«ÜÀ~¤H
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/8/16 ¤U¤È 12:04:21²Ä976½g¦^À³
²q·Q¤j»Pª©¤Wªø´Á§ë¸êªº¾Ô¤Í­Ì~~

ÀR«Ý«á¤Ñ8/18¤é½²±Ð±Â©ó²Ä¤Q¤»©¡°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|ªº¦¨ªG¤À¨É§a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/16 ¤W¤È 07:29:22²Ä975½g¦^À³
·sÃĤ½¥q§ä¥X¸ô ®ü¥~¶Ò¸êÉq

2018¦~08¤ë16¤é 04:10 ¤u°Ó®É³ø ¤å¡þ½²²Qªâ

www.chinatimes.com/newspapers/20180816000610-260210

¶Ô·~²³«H¥Í§ÞÂåÀø²£·~­t³d¤H¸·¦¨¥þ¤]Æ[¹î¨ì¡A¨Ã¤£¬O¥þ³¡·sÃĤ½¥q³£·|¨ì®ü¥~¡A­u®ü¥~±¾µPªº¤½¥q¤j³¡¤À³£°µ¨ì²Ä¤T´ÁÁ{§É¹êÅç¡A¦]¦¹¡A¤Ï¦Ó¬O¬°§Ú°êª§¥ú¡A¦P®É¤]¥i¥HÀ°¦£§Ú°êÁÈ¥~¶×¡C

¸·¦¨¥þ¤ÀªR¡A¥Í§Þ»sÃĤ½¥qªºµo®i¡A³q±`¥i³z¹L±ÂÅv¡B¨ÖÁÊ»P¦X¸ê¤TºØ¦X§@¥æ©ö¼Ò¦¡¨Ó´M¨D«´¾÷¡AÀò¨ú³Ð·sªº¬ãµo¸ê·½¡A±À°Ê²£«~¶i¤J¥«³õ¡C®Ú¾ÚDeloitte½Õ¬d¡A¥Ø«e¥þ²y¥«³õ¤Wªº¦X§@¥æ©ö®×¨Ò¤¤¡A¦³93¢HÄÝ©ó±ÂÅv¼Ò¦¡¡B6¢H¬O¨ÖÁÊ¡A¦Ó¦X¸ê¶È¥e1¢H¡F»OÆWªº±ÂÅv®×¼Æ¶q¥¿¼W¥[¤¤¡A³vº¥ªï¤W°ê»ÚÁͶաC¸·¦¨¥þ«Øij¡A¥ø·~»Ý¥ýÂç²M¦Û¨­¤½¥q¥¼¨Ó¤­¦~ªºÀç¹B¤è¦V¤Î¾ãÅé°]°È³W¹º¡A¦A®Ú¾Ú¤½¥q¥þ­±ªºÀç¹B¦Ò¶q¡A¤~¯à¶i¤@¨B§ä¨ì¾A·í¼Ðªº»P¦X§@¹Ù¦ñ¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/8/15 ¤U¤È 04:17:57²Ä974½g¦^À³
½²±Ð±Â

²¦·~©ó Johns Hopkins Hospital, Baltimore

¦¨ªø©ó Massachusetts General Hospital, Boston

©^Äm©ó UCLA Medical Center, Los Angeles

¤T¤jÂå°|¤À§OÀò±o U.S. News ¥þ¬ü³Ì¨ÎÂå°|ªº ²Ä 3 , 4 , 7 ¦W

www.usnews.com/info/blogs/press-room/articles/2018-08-14/us-news-announces-2018-19-best-hospitals

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:¤ß®®¥ÍÂå
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!